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Tuberculosis is one of the most prevalent diseases worldwide, and is the most frequent 
infectious cause of death. Diabetes is also one of the most common non-communicable 
diseases worldwide, with substantial increases in low-and-middle income countries in 
recent years. Due to the synergy between these two diseases, low-and-middle income 
countries are facing difficulties to control both diseases, largely because there is no 
adequate information on tuberculosis-diabetes comorbidity.  This study sought to 
improve the understanding of the co-occurrence of tuberculosis and diabetes in Peru, with 
the overarching aim to provide critical evidence to inform Peruvian disease control and 
health prevention programs.   
Methods 
First, we conducted a systematic review and meta-analysis in double high burden 
tuberculosis and diabetes countries was done to evaluate the role of Diabetes on 
Tuberculosis treatment outcomes.  Second, to evaluate the epidemiology of diabetes in 
Peruvian tuberculosis patients, we conducted a cross-sectional study of 484 tuberculosis 
patients in Lima, evaluating diabetes prevalence and risk factors for the co-occurrence of 
tuberculosis and diabetes.  Finally, mortality and factors associated with diabetes among 
tuberculosis multi-drug resistant (MDR-TB) patients in Lima was done using the 
information on the 1999 MDR-TB patients at the National Tuberculosis Program in Peru.   
Results 
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 In the systematic review, diabetes was associated with an increased risk for poor 
treatment outcomes among tuberculosis patients.  Among Peruvian tuberculosis patients, 
diabetes was associated with older age and higher body mass index (BMI).  In the cohort 
study among MDR-TB patients enrolled in Lima between 2010 and 2013, higher 
mortality was found among patients with diabetes, and MDR-TB patients with diabetes 
were associated with older age and higher BMI.   
Conclusions 
Tuberculosis-Diabetes comorbidity is more common in low-and-middle income countries 
like Peru than HIV.  The presence of diabetes is associated with poor tuberculosis 
treatment outcomes and may put in jeopardy the advances in tuberculosis control in high 
burden countries. Considering the increasing incidence of diabetes in low-and-middle 
income countries, an adequate programmatic management involving both health 
programs (tuberculosis and diabetes) is required to reduce the burden of this comorbidity.  
Challenges at the health system level involving an adequate screening, including glucose 
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1. Chapter One: Introduction and Review of the Literature 
 
1.1 Tuberculosis and Diabetes 
Tuberculosis (TB) is one of the most ancient diseases in the history of humankind and 
one of the most prevalent among the communicable diseases until the present day (1). 
TB, which is caused by the bacteria Mycobacterium tuberculosis, was the first disease to 
be involved in a randomized clinical trial(2), and is one of the infections most studied in 
the last years (especially after the emergence of AIDS in the 1980s), but diagnostic tools 
remain poor and therapeutic options available are still imperfect (most of the drugs used 
in TB treatment are toxic, with several adverse events and long treatment times).  
Furthermore, drug-resistant Mycobacterium tuberculosis strains, such as multidrug-
resistant (MDR-TB)(3) and extensively drug-resistant (XDR-TB)(4) are increasingly 
common, increasing the burden worldwide, especially in low- and middle-income 
countries(5).  The usual location for TB is the lung, but it can affect many areas in the 
body, including bones, eyes, bladder and other organs(6).   
 
Diabetes Mellitus (DM) is chronic disease and is classified in two types:  type 1 (DM-1), 
which is defined as deficiency in insulin production, and type 2 (DM-2), defined as an 
insulin resistance, is a major public health problem in the present day and, like TB, is 
more prevalent in urban areas(7).  As a one of the most prevalent non-communicable 
diseases, DM-2 is rising in low and middle-income countries in recent years(1, 8).  DM-2 
is a disease of insidious onset, with an often-late diagnosis, most frequently affecting 
middle and old-aged people; however it is increasing in young population in recent 
years(9-11).   DM-2 is characterized by high levels of blood glucose, producing 
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macrovascular and microvascular damage, and the clinical manifestations can be 
neuropathy, nephropathy, atherosclerosis and others(12).  Unfortunately, there is not a 
cure yet, and the therapy is for life, dealing with adherence problems and complex 
approaches (diet, lifestyle behavior and complex drug therapy).  Comorbidities is one of 
these problems in DM-2 patients, because is very common for patients to have more than 
one comorbidity, which can makes it difficult for the patient to maintain adequate blood 
glucose levels (13). 
 
The association between TB and DM-2 has been known for many years:  Bouchardat, 
one of the first doctors who studied DM (14), reported “tubercles” in DM patients 
lungs(15). At the beginning of 1900s, the frequency of DM among TB patients were 
around 50% (16). A manuscript published in 1957, reported a list of case series of TB-
DM patients from 1930 to 1953, showing an mortality frequency among TB-DM patients 
between 11 to 100%(17). Nowadays, the association between TB and DM is supported 
by evidence that shows the association of bad TB treatment outcomes among TB-DM 
patients(18) and higher risk of TB infection among DM patients(19), increasing the 
double burden in these two diseases. 
 
In this context, with the recent decades of increasing incidence of not only communicable 
but also non-communicable diseases (NCDs), the TB-DM epidemic is leading to a double 
burden in low and middle-income countries (where it is possible to find a DM-2 
prevalence among TB patients close to 30%(20)), affecting not only the population 
health, but also, because affects middle-aged population who are usually the economic 
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support of their homes, the socio-economic development in these settings (21). After the 
re-emerging of TB in the last 30 years, specially with the increased incidence of MDR-
TB and XDR-TB cases worldwide, this relation between TB and DM (specifically with 
DM-2) should be studied further, because there is a lack of evidence in different fields 
such as diagnostics, treatment (at patient level), but also in operational research and 
health systems research, to provide a better management to these affected 
communities(22).  
 
1.2 TB and DM interactions: Physiological, Clinical and Therapeutic issues 
 
1.1.1 Physiological interaction between Tuberculosis and Diabetes Mellitus 
The association between TB and DM-2 began to receive attention in the 1900s (23, 24), 
but remains to be completely understood until today.  One of the key concepts requiring 
research is the direction of this association; it is unclear whether TB infection makes 
patients more prone to development of DM-2 or whether DM-2 status increases 
susceptibility to TB infection(22, 25).  While some studies support the hypothesis that TB 
leads to DM-2 (26, 27) because it creates a hyperglycemic state during infection and 
treatment, the majority of evidence seems to indicate that DM is a risk factor for TB(19). 
 
DM-2 is a multi-organ disease affecting heart, lung, kidney, eyes, and brain, among other 
organs (28).   The management of DM-2 is complex because it involves drug treatment, 
patient education, and close control of complications (such as cardiovascular or renal 
problems) (29).  Obesity is one of the most important, if not the most important, risk 
factor for DM-2 (30, 31).  However, not all overweight individuals develop DM-2: some 
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individuals are more susceptible because they are unable to adapt to higher caloric intake. 
The key components required to adapt to increased energy intake are in the pancreas(32).  
The islet β cells are responsible for maintaining normal levels of glucose, reducing the 
risk of insulin resistance and increasing subcutaneous adipose tissue rather than visceral 
adipose tissue (13). In diabetic patients, these cells are unable to compensate an α-cells 
increase glucagon secretion, causing uncontrolled hyperglycemia and insulin resistance, 
and leading finally to onset the of diabetes (33). 
 
The immune response in individuals with DM-2 is not entirely understood too.  Some 
studies have reported that an increase in adipose tissue also increases the production of 
pro-inflammatory cytokines (such as TNF- α, IL-6, IL-8, IL-12)(34-38).   Studies in mice 
with DM-2 and TB showed increased pro-inflammatory cytokines (TNF- α, IFN-γ and 
IL-1b) with worse outcomes resulting in mice with TB and not DM-2 (39, 40). 
Adipocytokines (cytokines produced by the adipose tissue) is related in inflammatory 
process in obesity and DM(41), and the dysregulation of these adipocytokines can be 
related in the increased risk of TB among DM patients(42). Regarding a specific genetic 
expression in TB-DM patients, a pilot study found a reduction in the expression of two 
genes related to the macrophages (important in the immune response to M. tuberculosis): 
HK2 and CD28(43).   Furthermore, there is evidence about tissue damage (which is 
closely related with clinical severity) among TB-DM patients:  Tissue Inhibitors of 
Metalloproteinase (TIMPs) and Heme Oxygenase-1 (HO-1) were associated with more 
tissue damage, and increased plasma levels of HO-1 and TIMP-4 were found among TB-
DM patients compared with TB non-DM patients(44).  
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1.1.2 Clinical presentation of Tuberculosis and Diabetes 
The clinical presentation among TB-DM patients compared with TB-non-DM patients 
has some differences: radiographic findings showed atypical presentations in TB-DM 
patients compared with TB non-DM patients (lower location vs apical location in the 
lung) (45) and lung cavities are more frequent in TB-DM(45-47).  In a study evaluating 
MDR-TB patients with and without DM, a higher frequency of cavities were found 
among the DM patients(48).  Glucose control has an important role too: patients who had 
an uncontrolled DM had higher odds to present lung cavities(46, 49).  
 
There are also differences in the rate of smear and/or culture sputum conversion (usually 
used as a proxy of good TB treatment outcome and as a treatment  follow-up biomarker): 
studies showed TB-DM patients takes longer to have a negative sputum test compared 
with non-DM(46, 47). Also, as in cavities, uncontrolled DM patients (patients with an 
HbA1c >7%) have higher odds to have 2nd month culture positive compared with non-
DM patients(46). 
 
1.1.3 Treatment of Tuberculosis and Diabetes 
There are also challenges in TB treatment among DM patients, affecting treatment 
outcomes directly.  An example is TB treatment: weight (specifically overweight and 
obesity is a problem in TB-DM patients) can affect rifampicin pharmacokinetics (50), but 
still there is not enough evidence if there is a different pharmacokinetics patter in TB-DM 
compared with TB-non-DM(51, 52). 
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There is not enough evidence of which DM treatment (insulin or metformin) is better for 
TB patients.  In one hand, the first choice usually is insulin (an injectable hypoglycemic 
drug), which controls faster than other DM drugs the glucose level, however, the risk of 
hypoglycemia in patients with poor access to daily glucose measurement (such as TB 
patients, who usually don’t have access to health insurance and/or money to cover a 
glucometer) is high. In the case of metformin (an oral hypoglycemic drug), is safer and 
doesn’t require the same glucose control of insulin, but it has gastrointestinal adverse 
events (nausea, vomits) that can challenge the adherence to TB treatment(22). However, 
regarding metformin, there is preliminary evidence of beneficial effect of metformin, on 
the growth of M. tuberculosis, making metformin, regardless its role as DM drug, a 
potential candidate for co-adjunct drug in TB therapy(53), but further research is 
required.   
 
1.3 Epidemiological global status of Tuberculosis and Diabetes Mellitus 
 
1.3.1 Worldwide situation of Tuberculosis 
TB, along with HIV infection, continues to be one of the most prevalent infectious 
diseases in the world, with 10.4 million new cases in 2015 and 1.4 million deaths, 
ranking with HIV as the leading cause for death from an infectious disease (54).  TB is 
commonly termed a “poverty disease”(55) and it has significant societal impact, 
particularly among economically active segments of the population (56).  The estimated 
population infected with M. tuberculosis is one-third of the world’s population, and 
among those infected, 5% to 10% develop active TB(57).  The key components for 
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worldwide control of TB are early detection of TB patients and cure rates high enough to 
interrupt transmission(6). 
 
Progress has been made on several goals within the Global Plan to Stop TB 2011-
2015(58),  such as the decline of global incidence of TB in the last 2 years(59). However 
the rise of such complications as MDR-TB and XDR-TB, and comorbidities such as HIV 
and DM-2 are putting at risk the final goal of worldwide TB elimination by 2050(58).  
 
1.3.2 Worldwide situation of Diabetes 
In 2015, there were an estimated 415 million people living with DM worldwide, causing 
almost 5 million deaths in 2015(8). The estimated number of people with DM is 
projected to increase to 642 million by the year 2040, with a majority of DM affected 
populations living in low-resource settings (the estimate for 2015 was 75%)(8). A 
significant challenge is represented by the undiagnosed status of up to 179 million people 
with DM, leading with a late detection and the consequent presence of DM 
complications. The cost of DM is estimated to be 11% of total health spending in adult 
populations (8, 12).   
 
One of the problems associated with DM (specifically DM-2) in low-middle income 
countries (LMICs) is the increased incidence of cases, affecting mostly middle-age and 
older population, struggling with their economy and development(7, 60). Also, in many 
of these countries, health systems are not prepared to manage DM-2, because around 
90% of the expenditure on DM-2 is in high-income countries, so LMICs DM-2 
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population is vulnerable to related complications such as dialysis, limb amputation, 
blindness and others(7).  However, high-income countries also have difficulties 
successfully engaging patients in care:  one study in US showed around only 20% of 
DM-2 patients reached control goals (HbA1c, Blood Pressure, low-density lipoprotein 
cholesterol plus no smoking)(61). 
 
1.3.3 Worldwide situation of Tuberculosis-Diabetes Mellitus  
TB-DM comorbidity has been described increasingly during recent years, especially in 
low-and-middle income countries. Evidence shows a worst clinical presentation among 
TB-DM compared with TB non-DM, however there is no evidence on what is the best 
DM treatment in a situation of TB-DM, or how affects the immune response to TB 
treatment outcomes among TB-DM patients.  However, predictions about how DM 
affects TB control were done, for example  one projection based on a mathematical 
model showed how the increase of DM prevalence might jeopardize the reduction in TB 
incidence observed during recent years (62):  with a 10% overall DM prevalence (based 
on the International Diabetes Federation –IDF- estimates in 2013), the incidence of TB 
will increase by 3% in 2035 compared with the estimated incidence without an increase 
in DM prevalence; furthermore, if the scenario considers that DM is a multi-factorial 
disease and factors such as obesity are increasing and DM prevalence is estimated to be 
12.5%, the model estimates a change in TB incidence of 8% in 2035, showing how 
increasing prevalence of DM may directly affect the incidence of TB in coming years. 
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Unfortunately there is no information in the last Global Tuberculosis Report (2016) or in 
other World Health Organization o global report documents about TB-DM numbers 
worldwide (in contrast to TB-HIV figures for example), making it difficult to understand 
the real situation of this comorbidity(59). In 2011, the World Health Organization 
(WHO) in collaboration with the International Union Against Tuberculosis and Lung 
Disease, prepared the first framework for the management of TB-DM based on the 
evidence available at the moment, exposing the weakness of this evidence, and asking for 
more research in the area(63).  Based on the epidemiology of TB and DM separately, it is 
possible to observe that among the 10 countries with highest burden of each disease, 7 
countries (Brazil, India, China, Indonesia, Bangladesh, Pakistan and Russia) appear in 
both lists(7, 59)(Figure 1.1). 
 
1.4 Epidemiological situation in the Americas of Tuberculosis and Diabetes Mellitus 
 
1.4.1 Tuberculosis situation in the Americas  
TB in the Americas region has already reached the goal for 2015 of 50% incidence 
reduction (since 1990 there has been a decrease in TB incidence from 56 per 100,000 
habitants to 29 per 100,000 habitants), however TB is still a problem in countries such as 
Brazil, Bolivia, Haiti and Peru(59).  In 2016, WHO reported that of 480,000 cases, were 
2.9% were MDR-TB among new cases in the Americas (59).  Comparing 1990 data with 
2013 data, it is possible to observe that the percentage of patients younger than 15 years 
old increased slightly from 3.3% to 5.4%, but the ratio male/female remained stable 
during the same period  (1.6 to 1.7)(59).  
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1.4.1 Diabetes Mellitus situation in the Americas  
Latin America is undergoing an epidemiologic transition, with notable increases in the 
prevalence of hypertension, DM and hypertriglyceridemia, reaching levels comparable to 
the US and other developed countries (64).  In the case of DM specifically, the estimated 
prevalence in the Americas in 2013 was 8% in the adult population, however this number 
is expected to increase in 60% by 2035(8).  Among the countries with the highest number 
of people with DM are Brazil, Colombia and Argentina(8),  and the countries with 
highest prevalence are Puerto Rico, Nicaragua and Dominican Republic (with prevalence 
higher than 11%).  Regarding mortality, DM was the cause of 11.6% of all deaths in the 
region(8), increasing the burden among these countries. 
 
A study in Argentina, Chile, Colombia and Mexico showed that in the period 2000-2011, 
80% of the years of life lost due to DM were in people 50-74 years old (Mexico showed 
the biggest average lost)(65).  Another study in Argentina, Chile y Uruguay showed a 
high prevalence of obesity, dyslipidemia and other risk factors (including DM-2 and 
Metabolic Syndrome prevalence of 12.4% and 37.4% respectively). These numbers 
reflect how the DM problem is increasing rapidly among Latin America countries, 
affecting the health costs (around US$65 billion in Latin America in 2000(66)). 
 
1.4.1 Situation in the Americas of Tuberculosis-Diabetes Mellitus 
Mexico and other countries are starting to have problems with TB-DM, in part due to the 
increase of DM incidence.  Mexico, for example, reported around 20% of TB patients in 
the period 2000-2012 had also DM-2 (67).  Most of them were female and with older age.  
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Other studies showed a greater severity in TB-DM cases, such as more lesions on chest 
X-ray and longer time with positive culture (47, 68, 69), which leads to worse treatment 
outcomes. 
 
In Brazil, the number of TB-DM cases is increasing(70).  One study in 2009 found that 
TB-DM patients in Brazil were older and more likely to die from TB than TB patients 
without DM (71). Another study in Chile showed a DM prevalence of 15.6% among TB 
patients (72).  Similarly, to TB-DM worldwide data, there is not reliable data for TB-DM 
in Latin America because it is not routinely captured. 
 
1.5 Situation in Peru of Tuberculosis and Diabetes Mellitus 
 
1.5.1 Tuberculosis situation in Peru  
Among the Latin American countries, Peru reports a high incidence of pulmonary TB 
(121 per 100,000 habitants)(54) and a growing incidence of MDR-TB, with a 4.5% 
increase from 1996 to 2004 (73).  An estimated 58% of TB cases are concentrated in the 
capital city of Lima (74) and the majority of Peruvian TB patients are urban population.  
Despite the low prevalence of HIV when compared with the concentrated epidemic in 
some sub-Saharan African countries (75), the rise of MDR-TB incidence, years of 
poverty, and political conflict have fostered increasing TB incidence along with the 




There have been some changes in the demographics in recent years: the 2016 WHO TB 
Report showed an increase of young people (<15 years-old) and increase in the 
male/female ratio from 1.3 to 1.6 in the period 1990-2013 (59).   Additionally 40% of 
MDR-TB cases are new cases with an increasing number of XDR-TB cases(59). 
 
Since the 1990s, Directly Observed Treatment (DOT) has been the therapeutic approach 
for the treatment and control of TB in Peru (76).  DOT consists of an intensive 2-month 
phase during which Isoniazid (H), Rifampicin (R), Ethambutol (E) and Pyrazinamide (Z) 
are administered in daily doses, followed by 4 months of bi-weekly doses of Isoniazid 
and Rifampicin (three times per week since 2014).  The therapy is available in all health 
centers under the purview of the Ministry of Health. Patients attend these facilities for 
free TB diagnosis and treatment, including management of comorbidities such as HIV, 
depression and DM.  Diagnostic tests for disease control include sputum smear for all 
cases of suspected TB and culture for all TB cases. In recent years, the growing MDR-TB 
epidemic has necessitated scale-up of universal testing for drug-resistant TB (77). It is 
evident in this context (including other factors such as social inequality(78, 79) or 
comorbidities such as depression(80)) that TB is, regardless of all the efforts since the 
1990s, still far from being controlled in Peru. 
 
1.5.1 Diabetes Mellitus situation in Peru 
There is an increased number of studies in the last 5 years evaluating DM-II prevalence 
in Peru, with estimates around 9% in persons over 35 years old (81, 82) and pre-diabetes 
(defined as a fasting plasma glucose between 100-125 mg/dl) prevalence of 17.1%(81).  
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However, there is not a national register of DM patients, so potentially this prevalence is 
underestimate.  Also, obesity, a key risk factor for DM-II has a prevalence in urban areas 
around 25% (31). 
 
Unlike the Peruvian TB program, which has provided universal treatment and clinical 
care free of charge since the 1990s, the Peruvian program for NCDs has just started the 
implementation of a national program to provide free treatment for DM patients among 
poorer populations through National Health Insurance at the end of 2015. The increasing 
prevalence of diseases such as DM, requiring costly long-term care, constitutes a major 
challenge for the Peruvian health system. 
 
1.5.1 Situation in Peru of Tuberculosis-Diabetes Mellitus 
It is within this context that these two diseases – TB and DM – collide in Peru.  
Unfortunately, there is limited evidence on the real impact of diabetes on Peruvian TB 
patients, with only 4 observational studies were found in the literature.  One was a cases 
series conducted among hospitalized patients(83), a second one was on patients with high 
risk of TB drug resistance and describing among them DM characteristics(84).  The last 
two were publish in the last year years, one was comparing mortality between MDR-TB 
patients and non-MDR-TB patients, were DM was an independent risk factor for 
mortality(85) and the last one was a cohort study in a selected population in Lima, 
showing a there is difference in time to get a negative smear sputum test among TB-DM 
patients compared with TB-non-DM patients(86).  All these studies describing DM 
among selected population, so is difficult to extrapolate the results to the general 
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Peruvian TB population.  Two other studies explored pharmacokinetics of Rifampicin 
and Isoniazid in TB, TB-DM-II and TB-HIV patients, showing not difference in the 
median maximum plasma concentration (Cmax) among these populations(51, 52).  
 
There have been efforts to improve local data and evidence on TB-DM: since the last 
National TB Peruvian Guidelines in 2013, there is universal screening for DM-II among 
all new TB cases (however the screening rate is around 60% at national level) (Personal 
Communication), but updated information about the national prevalence of DM among 
TB patients is not still available. 
 
1.6 Programmatic issues in the management of Tuberculosis and Diabetes Mellitus  
 
One significant problem is the integration of TB programs with DM care at Primary 
Health Care (PHC) level.  One suggestion from WHO is the bi-directional screening for 
TB and DM-II among these groups of patients(63), but the evidence is still weak 
regarding screening of active TB among DM patients(22). 
 
However, there are some experiences at PHC level (and some of them are based in 
previous experiences on TB-HIV integration)(87, 88) with varying degrees of success, 
but gaps remain (for example, describing the optimum transition for TB-DM patients in a 
DOT clinic, having successfully completed their TB treatment, to a DM clinic with an 
adequate care engagement) to be filled in this complex health problem.  One study in 
Ethiopia showed most of the challenges are coming by the DM side:  the continuity of 
DM care after TB treatment, unavailability of DM treatment and lack of training on DM 
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among health workers(89), requiring further local operational research and 
implementation science studies to fill these gaps.  Glycemic control also is affected by 
poor capacity of health systems in LMICs to integrate health programs (Figure 1.2)(22). 
 
1.7 Rationale  
 
Both evidence and attention are increasing rapidly in the area of TB-DM.  However, there 
are gaps in epidemiological information, necessitating further research especially in 
LMICs such as Peru.  This dissertation will help to fill some of these gaps providing 3 
studies: a systematic review, a prevalence study and a cohort study.  
 
There have been several narrative reviews(25, 90, 91) and only two meta-analyses 
evaluating the TB-DM association(18, 19). One meta-analysis evaluated DM as a risk 
factor for TB (published in 2008)(19) and another examined the role of DM in TB 
treatment outcomes (published 2011)(18). Since these reviews (specifically the 
systematic reviews), there are reasons to evaluate new evidence on the topic: 
 
 There have been new studies since the most recent meta-analysis:  The last meta-
analysis incorporated studies published until December 2010.  Since then more 
than 50 new peer-reviewed articles have been published. 
 
 Study settings:  In both systematic reviews, a majority of the studies were 
conducted in developed country settings, such as the US and Japan.  Given the 
concern over the impact of TB-DM in LMICs countries and the publication in 
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recent years of more studies in low-resources settings, it is important to evaluate 
potential differences in outcome based on setting. 
 
Regarding the local status of TB-DM, DM is a growing problem in Peru, as in many 
developing countries.  Unfortunately, there is no detailed data about the prevalence of 
DM-II and the clinical characteristics of Peruvian patients living with DM.  Considering 
this, the proposed prospective prevalence study (with complete laboratory results, 
including HbA1c for all patients, and an initial exploration of potential risk factors in 
Peruvian TB-DM-II patients) provides the evidence required for actions at the National 
TB Program. 
 
Finally, MDR-TB is one of the most significant problems in TB control in Peru (59), and 
there are some reports suggesting worse clinical and treatment outcomes among this 
population(48).  As in the prevalence study, evidence is not available from Peruvian 
patients; this cohort study (which is the complete adult cohort of MDR-TB patients in 
Lima between 2010-2013) will therefore provide information on the characteristics of 
MDR-TB-DM-2 patients compared with MDR-TB non-DM patients, and also MDR-TB 
treatment outcomes among this population. 
 
1.8 Overall Goal and Specific Aims 
 
1.8.1 Overall Goal of the Study  
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A re-emerging TB epidemic combined with the continuous rise in DM prevalence in Peru 
is similar to other developing countries, creating a potential “perfect storm” with the 
collision of TB and DM.  Thus, the overall goal of this dissertation is to strengthen the 
evidence base on the TB-DM association in Peru and globally with a 3 studies: a 
systematic review of TB treatment outcomes among TB-DM patients vs. TB non-DM 
patients in countries with high burden of TB and high burden of DM; a DM prevalence 
study among Peruvian TB patients, evaluating clinical characteristics; and a cohort study 
to evaluate differences in treatment outcomes among MDR-TB-DM patients vs. MDR-
TB non DM patients in Peru. 
 
1.8.2 Specific Aims 
Specific Aim 1 
To conduct a systematic review to determine whether TB-DM patients have worse TB 
treatment outcomes than TB-only patients in countries considered as high burden 
countries for TB and DM.  
 
Specific Aim 2 
To determine the prevalence of DM in recently-diagnosed Peruvian TB patients and 
identify the clinical and social characteristics and potential risk factors for DM among 
Peruvian TB patients. 
 
Specific Aim 3 
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To determine the differences in treatment outcomes and patient characteristics in 





Figure 1.1 .– Countries with Tuberculosis and Diabetes double burden 
 
Definition of countries with TB-DM double burden dual high burden if they are listed by 
WHO as TB high burden country and as high DM prevalence country by the International 
Diabetes Federation  
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The impact of diabetes mellitus (DM) in persons with tuberculosis (TB) has recently 
received increased attention globally. A systematic review (studies published through 
Dec 2010) examined the association between DM and TB treatment outcomes, but the 
majority of included studies were conducted in high-income countries. Given the concern 
over the impact of diabetes in countries with a high burden of both TB and DM (TBhbc 
& DMhbc), many new studies have been published recently. We systematically reviewed 
the literature through 2015 to determine if the association differs by TBhbc & DMhbc 
settings.  
Methods  
The search was conducted in 6 bibliographic databases and all languages. We included 
cohort and case-control studies investigating treatment outcomes between TB patients 
with DM (TB-DM) and TB patients without DM (TB non-DM). Two reviewers 
independently screened abstracts, full-texts, and extracted data. The methodological 
quality and risk of bias of the included studies were assessed according to Newcastle-
Ottawa Scale. Random-effect meta-analysis was used for data synthesis and main 
analyses. 
Results  
The literature search yielded 16,770 articles; 355 full-texts were reviewed; of these we 
included 11 from TBhbc & DMhbc. TB-DM patients had an increased risk of death 
compared with TB patients in the pooled analysis (Pooled Relative Risk pRR=2.5, 
95%CI: 1.8-3.3; I2:51%); TB-DM patients had higher risk of poor outcome (treatment 
failure or death) compared with TB non-DM patients (pRR=2.6, 95%CI: 1.6-4.3; 
I2=69%). Among the studies with confirmed DM status, the pRR for Death was 2.5 
(95%CI 1.2-5.1; I2=48%) and the pRR for poor outcome was 2.5 (95%CI 1.5-4.2; 
I2=70%).  An asymmetrical funnel plot suggests potential publication bias. 
Conclusions  
TB-DM patients had higher risk of unsuccessful TB treatment outcomes compared with 
TB non-DM patients from TBhbc & DMhbc. Prospective and well-designed studies are 
needed to evaluate factors associated with poor treatment outcomes among TB patients. 
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The impact of diabetes mellitus (DM) on tuberculosis (TB) risk and treatment outcomes 
has received increased attention in recent years, considering the rising incidence of non-
communicable diseases (NCDs) in the past few decades(1) and a slowly declining global 
TB incidence (2).  The TB-DM epidemic is leading to a double burden in low and 
middle-income countries (LMICs), reaching levels of DM prevalence more than 20% 
among TB patients in some settings (3-10). 
 
Despite the achievements in the last years reducing TB incidence, the success of WHO’s 
End TB strategy (elimination of TB by 2035) can be affected by several factors including 
weak health systems, social determinants, DM and others(11).   Regarding DM, a 
projection based on a mathematical model showed how the increase of DM prevalence 
might jeopardize the reduction in TB incidence observed during recent years (12):  with a 
10% overall DM prevalence, the incidence of TB will increase by 3% in 2035 compared 
with the estimated incidence without an increase in DM prevalence.  Furthermore, if the 
scenario considers that DM is a multi-factorial disease and factors such as obesity are 
increasing and DM prevalence is estimated to be 12.5%, the model estimates a change in 
TB incidence, increasing by 8% in 2035.  These results suggest how increasing 
prevalence of DM may directly affect the incidence of TB in coming years(12). 
 
There is evidence that DM worsens TB clinical presentation and leads to poorer treatment 
outcomes and greater risk of death (13-17). Also, TB patients with DM have been shown 
to have  more lung damage and higher frequency of cavities(16), slower culture(13) and 
smear (16-18) conversion and higher risk of multidrug resistance (19). A systematic 
review published in 2011 summarized evidence on TB treatment outcomes among TB 
patients with DM (including 33 primary studies published until 2010), though only 5 
studies were conducted in high burden TB or DM countries. The review reported higher 
risk (RR: 1.7; 95% CI 1.4 -2.1) of poor TB treatment outcomes among TB-DM patients 
compared with TB non-DM(20). However, since publication, more than 60 papers have 
been published evaluating TB treatment outcomes among TB-DM patients, and many 
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from high burden TB and DM countries were published, providing new evidence for an 
update. The impact of TB-DM on patients in these countries should be evaluated, 
especially because most of the studies included in Baker et al review were not primarily 
designed to evaluate the association of TB-DM with TB treatment outcomes, and the 
methodological quality of these primary studies was not optimal, expecting a better and 
less biased studies in this new review.   
 
We aimed to evaluate if TB-DM have worse TB treatment outcomes than TB non-DM 
patients, updating the study published by Baker et al(20), but focused in countries 
considered with double high burden on TB & DM, with the goal to evaluate the impact of 




Search strategy and selection criteria 
The primary objective of this systematic review and meta-analysis is to estimate the 
difference in TB treatment outcomes between TB-DM patients and TB non-DM patients 
in countries high burden of TB and DM and was registered at PROSPERO Register 
(#42015026927).  We sought to identify peer reviewed, studies containing data on TB 
outcomes among patients with and without DM. We searched the following electronic 
scientific journal databases from the 1/1/1980 up to 30/04/2015; Medline (via PubMed), 
Embase (via Embase.com), AIM, LILACS, IMEMR, IMSEAR and WPRIM (via WHO 
global index medicus). The start date was chosen as by this point because the standard 6-
month TB treatment was in common use as a mainstay TB treatment thus TB regimens 
across studies should be more comparable(21). We used both MeSH and keyword terms 
(tuberculosis, diabetes mellitus, risk factor, outcome) in combination with standard 
Boolean operators to create a highly sensitive search strategy (see appendix 1). We also 
identified potentially relevant titles through conference proceeding searches, contacting 




The search was not narrowed beyond these broad categories in order to standardize 
search strings across databases and to maximize the search.  The literature identified from 
the databases noted above was combined into a single bibliographic database.  Duplicates 
of the retrieved studies were removed. Once this was completed, titles and abstracts were 
screened: the primary search included articles of all types, without any restriction on 
publication year or language of publication.  During secondary screening, review articles, 
editorials and letters, as well as those not meeting our inclusion criteria outlined above 
were excluded.  
 
Eligibility Criteria 
We included various study designs in the review: cohort studies (prospective or 
retrospective), case-control studies or any study with longitudinal follow-up of TB 
treatment outcomes. To define a country as a TB & DM double high burden country (TB 
& DM dhb), we considered if the country had comparative prevalence >10% in the adult 
population (over 20 years of age) (according to the IDF diabetes atlas)(22) and if is listed 
as high burden country for TB by WHO(2).  Regarding population, we included studies 
with patients on standard TB treatment(23), and exclude studies only focused in MDR-
TB treatment outcomes because they have different TB treatment length. DM status was 
defined as is defined in the primary study (medical records, fasting blood glucose, 
HbA1c). The primary outcome utilized in this review is TB treatment outcome.  We use 
the definitions for TB treatment outcome by WHO(24).   
 
Data Extraction and Quality Assessment 
Two independent reviewers (from among CU-G, PH, FP) were involved in the review of 
titles/abstracts and the full text of articles, and a third reviewer (JC) within the team 
solved the discrepancies. If the title/abstract record did not provide enough information 
for inclusion, then the full text was retrieved for full text screening. For the data 
extraction, the study team developed ad-hoc forms for data extraction and study quality, 
using the Systematic Review Data Repository (SRDR) on-line platform(25), with double 
data entry to reduce the risk of error in the abstraction process. The information 
abstracted included demographic characteristics (age, sex), country, year, DM definition, 
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anthropometric measures (Body Mass Index), glucose test (fasting blood glucose, random 
blood glucose, HbA1c), type of TB (pulmonary or extra pulmonary), number of episodes 
of TB, sputum smear and culture results and TB treatment outcomes. 
 
Regarding methodological quality of included studies, observational studies in general 
are prone to confounding and bias (in addition to the role of chance if the study is of low 
power to see the difference stated in the hypothesis) to some degree depending on the 
design. The source of bias of each full text study will be evaluated independently by each 
reviewer using Newcastle-Ottawa Scale (26), which is a tool for observational studies.  




The analysis was done use RevMan (version 5.3). We pooled measures of association on 
treatment outcomes, using inverse variance weighting in a random-effects model. We 
estimated heterogeneity with I2 statistic (a value greater than 50% will be considered as 
important statistical heterogeneity) and Chi-square test for heterogeneity (p value <0.05 is 
consider as significant heterogeneity). Also, forest plots were evaluated to examine the 
degree of overlap between confidence intervals of risk estimates of the included studies.  
To assess the potential risk of publication bias, a funnel plot was drawn (28). 
 
Role of the funding source 
The sponsors of this study had no role in the study design, development or in the 




The literature search yielded 16,770 articles; 94 full-texts were reviewed; of these 13 
were conducted in countries with a high burden of both TB & DM (Figure 2.1)(13, 14, 
16-18, 29-35). The TB characteristics of the primary studies are in Table 2.1 and the DM 
characteristics are in Table 2.2. These studies included 38,644 TB patients and 3,497 TB-
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DM patients in Brazil (4 studies), China (2 studies), India (4 studies), Indonesia (1 study) 
and Russia (2 study).  Eight of 13 studies were retrospective cohorts, 2 were case-control 
studies(34, 35) and DM definition was made mainly by medical records.  
 
11 studies remained eligible to pool to estimate an effect measure.  Patients with both TB 
and DM had an increased risk of death compared with TB patients without DM in the 
pooled analysis (Pooled Relative Risk pRR=2.5, 95%CI: 1.8-3.3; I2:51.1%) (Figure 2.1). 
TB-DM patients had higher risk of poor outcome (treatment failure or death) compared 
with TB-nonDM patients (pRR=2.6, 95%CI: 1.6-4.3; I2: 69%) (Figure 2.3). Only one 
study (13) reported sputum culture conversion as treatment outcome, showing no 
association with TB-DM status (adjusted OR: 0.9, 95%CI: 0.3-2.7). Only 3 studies 
reported TB treatment outcome adjusted by potential confounders(13, 29, 36) and one 
reported relapse as treatment outcome (crude OR: 2.4, 95%CI:0.6-10.4)(34). 
 
A sensitivity analysis was done evaluating studies with confirmed DM status, the risk to 
death was similar (pRR=2.5; 95%CI: 1.2-5.1; I2: 48%) and the same occurs with the risk 
for TB treatment outcome (pRR=2.5; 95%CI: 1.5-4.2; I2: 70%) (Figures 2.4 and 2.5).  
Regarding publication bias, the funnel plot was symmetrical (Figure 2.6), suggesting low 
risk of publication bias. 
 
Regarding quality of the studies, the NOS Quality Score was in overall 6.8, when the 
lowest had 6 and the highest had 8 as NOS Score.  The assessment of quality is explained 
in Table 2.3.  Regarding the quality of the body of evidence among the studies included 
in the meta-analysis, the outcomes are summarized in Table 2.4 using the GRADE 
approach.  The findings showed a low level of quality, mainly because all the studies 




Our results confirm the association found by Baker et al(20) on poor TB treatment 
outcomes among TB-DM patients, however our estimate were higher than theirs for risk 
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of death (pRR=2.5 vs pRR=1.9) and risk of poor TB treatment outcomes (pRR=2.6 vs 
pRR=1.7). The difference in magnitude of the point estimate can be explained because 
our review focused in LMICs countries with a high burden of both TB and DM.  DM 
care, as any chronic disease in LMICs, has a large economic burden in these settings(37), 
and requires adequate health monitoring and a stronger health system to provide 
diagnosis, care and treatment.  Studies in India(38) and Indonesia(39) showed how 
complex is DM care in these health systems, affecting DM care especially among poorest 
population, which also are in higher risk for TB.  
 
Epidemiological characteristics are also different by settings: in high-income countries, 
men usually have higher frequency of DM compared with women, unlike LMICs, where 
women have more DM than men(40). TB is still frequent in LMICs(2, 41), but in high-
income countries is more frequent among older population(42).  Age is a strong 
associated factor for DM, and because older populations in LMICs have inadequate and 
incomplete access to health care(43, 44), this population is at high risk for TB-DM 
comorbidity. 
 
Besides health systems factors related with TB-DM at LMICs, there are others:  
genetically DM is associated with higher risk in these populations (Latin America, South 
Asia and Africa populations)(45-47) in the same way as TB is associated with same 
populations(48-52).  Also, despite the last improvements in TB burden reduction 
worldwide, the number of cases is still high among these populations(2), and the 
projected increase of DM among same populations in the following years(22), would 
complicate disease control for TB-DM(53).   
 
Because many of the studies used in this review and in Baker et al(20) were not aimed to 
evaluate TB-DM association, there is a lack of confounding control in general: in our 
review only three studies (13, 29, 36) reported adjustment by confounders and in Baker’s 
review only 4 studies(54-57)(3 studies in USA and one in Taiwan). Regardless NOS 
Quality Score didn’t cover all sources of potential biases (and didn’t consider the role of 
chance too), we observed that none of included studies in our review considered to adjust 
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for important confounders such as HbA1c, comorbidities (as hypertension, renal failure), 
BMI (only one study (13) adjusted by BMI), DM treatment, smoking, and gender, which 
are related with DM mortality(58, 59).  Also, other reasons of death such as cancer 
(which are associated with DM)(60, 61), was not evaluated in these studies because TB 
specific mortality is not usually reported.  The overall summary of findings (showed in 
Table 2.4) confirms the low quality of the evidence. 
 
The strength of our review is the comprehensive search of TB-DM without restrictions of 
language in several bibliographic databases with broad search terms, because in many 
cases DM was not consider as an exposure, reason why we screened more than 16000 
hits evaluating TB treatment outcomes in general with the aim to reach as many DM 
exposure measures as possible.  Regarding the restriction of year (1980), most of the 
studies using WHO regimen for drug sensitive TB (rifampicin-based regimens) were 
publish after 1980(62, 63), reason why there is not too much heterogeneity regarding TB 
treatment (and TB treatment length).  
 
There are some limitations, like any meta-analysis done among observational studies, 
mainly based on the quality of the included primary studies.  One was the definition of 
DM in the included studies, because DM status was not routinely assessed in TB 
programs and/or epidemiological TB studies in general, underestimating the association 
between TB-DM and poor TB treatment outcome. However, when sensitivity analysis 
was done in only studies with confirmed DM status (13, 14, 16-18, 29-33), the estimate 
direction for death and poor treatment outcome were kept. Also, hyperglycemia is very 
common in infectious diseases(64, 65), including TB, affecting DM diagnosis in TB 
patients (especially if it was done at TB diagnosis), increasing the risk of DM 
misclassification, because it can be a transient hyperglycemia episode rather than DM(66, 
67).  However, hyperglycemia status (no DM) are associated with poor TB treatment 
outcomes compared with normoglycemic TB patients(67).  Glucose control during TB 
treatment was not recorded in these studies, and this is an important factor to evaluate the 
severity of DM in general, furthermore, glucose control among TB-DM patients is also 
associated with TB treatment outcomes: a study done in Taiwan showed that poor 
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glucose control was associated with poor TB treatment outcomes among TB-DM patients 
(68).  
 
Our review confirmed the association between TB-DM and poor TB treatment outcomes 
in TB-DM double high burden countries, similar that founded in high-income countries.  
The risk for mortality and treatment failure should be evaluated in detail in future studies, 
looking for DM complications that can affect the success of TB treatment (renal failure, 
cardiovascular complications) and taking account known confounders in the analysis 
(such as HbA1c, BMI, gender).  Considering the ageing of TB population(42), and the 
strong association of TB-DM with age, there is a necessity to implement comprehensive 
TB-DM care in TB clinics, including close glucose monitoring and DM treatment as part 




Figure 2.1 – Flowchart for study selection  
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Error bars show 95%CIs. Risk Ratios and weights were derived from Inverse Variance 








Error bars show 95%CIs. Risk Ratios and weights were derived from Inverse Variance 
Random Effects model 
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Figure 2.4 – Risk of Death among TB-DM and TB non-DM in studies with 




Error bars show 95%CIs. Risk Ratios and weights were derived from Inverse Variance 
Random Effects model 
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Error bars show 95%CIs. Risk Ratios and weights were derived from Inverse Variance 
Random Effects model 
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Table 2.1. – TB Characteristics of included studies for the association between DM and TB outcomes 
 










Death Relapse Variables adjusted for outcome 
            
De Oliveira, 
2000 Case-control Brazil Pulmonary TB 361 NR 
Case 6(11%) 
Control 5 (5%)    
X  
Mathew, 2006 Retrospective cohort Russia Undifferentiated TB 1916 1656 (86.4%) 44 (2.3%)   X 









cohort Indonesia Pulmonary TB 634 602 (95.0%) 94 (14.8%) X X X 


























cohort Brazil Undifferentiated TB 17047 24145 (77.7%)* 1797 (5.8%)   X 
 Age, 
Institutionalization, 





















cohort China Pulmonary TB 1126 88 (7.8%) 182 (16.1%)  X X 
  
*Not reported among patients with TB treatment outcome info
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Table 2.2. – DM Characteristics of included studies for the association between DM and TB outcomes 
 













Case (%) DM Case Definition 
De Oliveira, 
2000 42.6 (NR)* NR NR NR NR NR Medical Records 
Mathew, 
2006 43.6 (NR) NR NR NR NR NR Medical Records 
Kourbatova, 






(18.9-22.8)a NR 57 (61.3%) FBG > 126 mg/dL 2 times 
Orofino, 
2012 39 (NR) NR NR NR NR NR Medical Records 
Sangral, 
2012 41.0 (NR) 50.1 (14.4) NR NR NR NR 
Medical Records, GOD-POD or 
OTTG 
Mi, 
2013 NR NR NR NR NR NR FBG > 126 mg/dL 2 times 
Nandakumar, 
2013 NR NR NR NR NR NR 
Medical Records, FBG > 126mg, 
RBG > 200mg or PPBS 
Reis-Santos, 
2013 NR 52 (14) NR NR NR NR Medical Records 
Ribeiro, 
2013 NR NR NR NR NR NR Medical Records 
Viswanthan, 
2013 42.4
b 49.9 (11.3) 17.9 18.9 (4.1) NR NR Medical Records, FBG > 126 mg/dL, OTTG 
Viswanthan, 
2014 NR 50 NR NR NR NR Medical Records, OTTG 
Hongguang, 
2015 NR 53 (45-64)
a NR NR NR NR Medical Records, FBG > 126 mg/dL, OTTG 
NR: Not Reported 
FBG: Fasting Blood Glucose; GOD-POD: Glucose Oxidase-Peroxidase Method; OTTG: Oral Glucose Tolerance Test; PPBS: Postprandial blood sugar 
a: Median (IQR) ; b : Median 
* Calculated from age-group information 
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Table 2.3. –Assessment of Quality by the use of the Newcastle-Ottawa Scale (NOS)* 
  
Study ID 

















of interest was 
not present at 
baseline 
Comparability of 
Cohorts on the 












2006         6 
Alisjahbana, 
2007         8 
Orofino, 
2012         6 
Sangral, 
2012         6 
Mi, 
2013         7 
Nandakumar, 
2013         7 
Reis-Santos, 
2013         8 
Ribeiro, 
2013         6 
Viswanthan, 
2013         7 
Viswanthan, 
2014         7 
Hongguang, 
2015         7 
 
*For cohort studies 
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Table 2.4. –Assessment of overall evidence quality using GRADE methodology* 
 
Quality assessment Number of patients Effect 
Quality Importance # of 
studies Study design 
Risk of 
bias Inconsistency Indirectness Imprecision 
Other 




Death (assessed with: study defined measures) 
11 observational studies 
not 




(1.80 to 3.33) 
⨁⨁◯◯ 
LOW CRITICAL 
Bad Treatment outcome (Death and Failure assessed with: study defined measures) 
8 observational studies 
not 




(1.61 to 4.29) 
⨁◯◯◯ 
VERY LOW CRITICAL 
 
 
*For studies included in the meta-analysis
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Diabetes mellitus (DM) prevalence is increasing around the world, especially in low and 
middle income countries (LMICs). Tuberculosis (TB) is still a public health problem in 
LMICs, such as Peru, where there is limited evidence about DM prevalence and its 
associated factors among TB patients.  We evaluated the prevalence and associated 
factors of DM among TB patients in Lima, Peru. 
 
Materials and Methods 
We conducted a cross-sectional study based in the Peruvian research site of the 
TANDEM Consortium (www.tandem-fp7.eu). Adults from 4 health centers in Lima with 
a recent diagnosis of TB were screened for DM using HbA1c. Clinical, anthropometric 
and socio-demographic characteristics were collected. Poisson regression modeling with 
robust variance was used to calculate prevalence ratios for associated factors. 
 
Results 
484 TB participants were enrolled, and 44 were determined to have DM (Prevalence 
9.1%; 95%CI: 6.8%-12.0%); 28 had pre-existing DM and 16 were newly diagnosed at 
screening. DM prevalence among those over 35 years of age was 18.1% (95%CI: 13.5%-
23.8%) and 1.9% (95%CI 0.8%-4.4%) among those under 35. Pre-diabetes prevalence 
(defined as HbA1c between 5.7%-6.4%) was 25.6% (95%CI: 21.9%-29.7%) among all 
participants and 27.3% (95%CI: 21.8%-33.7%) among individuals over 35 years of age. 
In Poisson regression, age over 35 years old and a BMI higher than 30kg/m2 were 
associated with DM in adjusted analyses. When restricted to participants over 35 years of 
age, these risk factors did not change.  
 
Conclusions 
DM was more common in TB patients over 35 years old and in obese individuals. Further 
studies are needed to evaluate pathophysiology, epidemiology, and transmission patterns 
within TB-DM populations. 




Among the Latin American countries, Peru reports one of the highest incidences of 
pulmonary tuberculosis (TB) (119 per 100,000 habitants in 2015)(1). 5.3% of Peruvian 
TB patients have multi-drug resistant tuberculosis (MDR-TB), and treatment success is 
reported to be 79%.  Primarily an urban disease, an estimated 58% of TB cases are 
concentrated in the capital city of Lima (2).  
 
Diabetes mellitus (DM) is a growing problem in Peru, as in many low and middle income 
countries (LMIC)(3). Recently, some studies conducted in Peru reported prevalence 
estimates between 3.9% to 7.4% (4-7): two studies focused on Lima (4, 5) but were 
conducted 10 years ago while the other two recent studies had a better national 
representation (6, 7). Obesity seems to be the driver of DM in Peru:  the Population 
Attributable Risk (PAR) of obesity for DM was estimated to be 23.9%(7). 
 
It is within this context that these two diseases – TB and DM – collide in Peru, though, 
there is little evidence regarding the association between TB and DM in our setting. One 
study reported a DM prevalence of 11% among TB patients with high risk of MDR-TB 
(8); however, DM was defined using medical records, so this result may be an 
underestimate.  A small cohort study found a delay in culture conversion among TB 
patients with DM compared with TB patients without DM, but the sample size was small 
and DM was defined only by clinical records(9). Another study showed that DM history 
was associated with mortality among MDR-TB patients in Lima(10).  However, as in the 
previous study, the DM definition was mostly based on medical records, so there is a risk 
of misclassification of DM exposure. 
 
Considering the lack of information about DM prevalence among TB patients in Peru, the 
main objective of this study is to evaluate the prevalence of DM and its associated factors 
among Peruvian TB patients in TB clinics at 4 Primary Health Centers across Lima. 
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Materials and Methods 
 
Study design and Study Population 
This was a cross-sectional study conducted in 4 Primary Health Centers in Lima, Peru 
from January 2014 to November 2015.  Patients were enrolled at TB diagnosis and before 
initiation of TB treatment. This cross-sectional analysis is part of the activities of the 
TANDEM Consortium (www.tandem-fp7.eu).  TANDEM is a multi-site project whose 
main objective is to provide evidence regarding the association of TB and DM(11). We 
included patients recently diagnosed with Pulmonary TB who were older than 18 years 
old and who had provided a blood sample for HbA1c and blood glucose. For this cross-
sectional analysis, the minimum sample size calculated (considering a significance level 
of 5%, a prevalence of 7%, and precision 2.5%) was 401. 
 
Study definitions 
We defined individuals with pulmonary TB as any individual who initiated treatment at a 
Directly-Observed Therapy–Short Course (DOTS) clinic, as per the Peruvian National 
TB Guidelines(12).  We defined DM as a HbA1c higher than 6.5% and/or having a 
previous DM diagnosis. All participants were tested for HbA1c as per World Health 
Organization (WHO) recommendations for DM screening(13, 14), regardless of their 
previous DM status. A study in Peru showed that the use of HbA1c compared with 
Fasting Blood Glucose (FBG) detected more DM cases(15). Pre-diabetes was defined as 
a HbA1c value between 5.7% and 6.4%(16). Body Mass Index (BMI) and Waist-to-Hip 
Ratio (WHR) were measured as a proxy for obesity:  underweight was defined as 
BMI18.5kg/m2, normal weight a BMI between 18.5kg/m2 to 25kg/m2, overweight a 
BMI>25kg/m2, and obese higher than 30kg/m2. Socio Economic Status (SES) was 
calculated using an index based on the approach proposed by Vyas & 
Kumaranayake(17).  This SES index classified the study population from the poorest to 
the richest using quintiles, using Principal Component Analysis (PCA) in household 
characteristics, access to utilities and ownerships in absence of income and/or 
expenditure measurements, which usually are linked with recall bias, seasonality and 




We used REDCap 6.9.1(18) for data collection and management, and STATA 13.0 
(StataCorp, Texas, USA) for statistical analysis. Categorical variables were presented 
with their frequencies and continuous variables were summarized using median and 
interquartile ranges (IQR). Analyses between groups was done using the Mann-Whitney 
U test for non-parametric data, and using the chi-squared test for categorical variables. 
The main analysis used a Poisson regression model with robust variance to estimate 
crude and adjusted prevalence ratios (19), evaluating factors associated with the presence 
of DM at TB diagnosis. A sub-analysis was performed with patients over 35 years old 
using the same approach. 
 
Ethics 
This study was approved by the Institutional Review Board (IRB) at the Universidad 
Peruana Cayetano Heredia with permission from the Peruvian National TB Control 
Program.  TANDEM, as the parent study, also had approval as the TANDEM 





669 patients were eligible and 484 (77.8%) were enrolled (Figure 1). We didn’t find a 
statistical difference between those enrolled and those not, and the main reason for 
refusing to participate was the number blood samples (5 tubes of 8ml). Participant 
characteristics are listed in Table 3.1.  Forty-four (9.1%; 95% CI: 6.8%-12.0%) 
participants were classified as living with DM; of which 16 (34%) were diagnosed with 
DM at enrollment, 20 (23%) within less than 1 year prior to enrollment, 11 (25%) within 
1-5 years prior and 7 (16%) more than 5 years prior to enrollment.  The median age 
among TB patients with DM was 51 years (IQR: 45.0-58.5) compared to 28.5 years 
(IQR: 22.0-40.0) among those without DM. DM prevalence among TB patients older 
than 35 years was 18.1% (95%CI: 13.5%-23.8%) in this age group compared to 1.9% 
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(95%CI: 0.8%-4.4%) among TB patients < 35 years of age. Only nine TB patients (1.9%) 
were HIV positive, of which only one was also diagnosed with DM.  The median BMI 
among TB patients with DM was 24.6kg/m2(IQR: 21.7-27.5) compared to 
21.8kg/m2(IQR: 19.8-24.0) among patients without DM. Almost half (47.7%) of the 
participants with DM were overweight or obese, compared with 17.4% among TB non-
DM (p<0.05).  Among TB patients with DM, 10 (22.7%) had a previous TB episode 
compared to 139 (31.6%) among patients without DM (p=0.23). 
 
Regarding pre-diabetes, the prevalence in the study population was 25.6% (95%CI: 
21.9%-29.7%) and among participants over 35 years old was 27.3% (95%CI: 21.8%-
33.7%). Among TB patients with pre-diabetes, 48 (38.7%) had a previous TB episode, a 
higher percentage compared with TB-DM and TB non DM (91 participants, 28.8%); 
median Body Mass Index (BMI) was 21.6 (IQR: 19.7-23.6), median HbA1c was 5.8% 
(IQR:5.7-6) and median Waist-Hip Ratio (WHR) was 0.89 (IQR:0.84-0.93), showing a 
higher BMI and WHR in participants with pre-diabetes compared with non-DM 
participants.  
 
Crude and adjusted regression analysis using a Poisson Regression model with robust 
variance are shown in Table 3.2. Age and a BMI higher than 30kg/m2 were associated 
with DM in the adjusted analysis.  In Table 3.3, we can observe only age over 65, 
previous TB episode and a smear positive result was associated with pre-diabetes 
compared with TB non-DM participants.   
 
We conducted a sub-analysis in the population over 35 years of age.  Median HbA1c was 
5.6% (IQR: 5.3-6.0), median BMI was 25.6 kg/m2 (IQR:20.4-25.6) and median WHR 
was 0.90 (IQR: 0.87-0.95).  We display the crude and adjusted regression analyses for 
participants over 35 years old in Table 3.4.  The factors associated with TB-DM among 






Our results show a high DM prevalence among TB patients (9.1%), particularly in 
patients older than 35 years of age (18.1%). These results are higher than the national 
estimates (around 6% and 7% of DM prevalence in people over 35 years and over 25 
years respectively)(6, 7).  
 
Regarding age, several studies have shown that age is an important factor associated with 
DM among TB patients (20-26), consistent with our results. DM is more prevalent in 
older people (16, 27); however, in recent years, the mean age of individuals with DM has 
been decreasing and individuals with DM are increasingly younger (3). Thus, there is an 
increasingly greater age overlap between populations with DM and TB, given that 
younger individuals are generally at greater risk for TB (28).  
 
Almost 50% of TB-DM participants knew about their DM status at least 5 years before 
their TB diagnosis.  Considering that DM increases the risk of active TB (29), 
interventions to prevent TB within DM populations, especially in areas with high TB 
prevalence, are urgently needed. These interventions are especially needed in Peru, where 
the prevalence of latent TB, although unknown, is likely high given that in similar 
settings such as Mexico the prevalence of latent TB is around 50% (30). These 
interventions should include intense glucose control, because most of our TB-DM 
patients had uncontrolled glucose (median HbA1c 10.3% with extreme values of 17%) 
and a history of irregular adherence to medication and medical control. Furthermore, 
there are studies showing the association of poor glycemic control with worse TB 
treatment outcomes(8, 31, 32).  
 
Obesity was also associated with DM among this TB population and there are other 
studies confirming our findings of an association of higher BMI with DM(22, 33, 34) 
among TB patients. Active TB is well known to be associated with under-nutrition (35, 
36), and this nutritional condition increase the mortality among TB patients(37).  Also, 
some studies showed the role of overweight/obesity (based on BMI) as a protector factor 
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for active TB(38, 39), and overweight/obese TB patients had lower risk for mortality 
compared with TB patients with undernutrition(37).  Overweight and obese patients have 
differences in immune response, basically through adipose tissue(40): for example 
adypocytokine (cytokines produced by adipose tissue) plasma levels are altered in TB-
DM patients compared with TB non-DM patients, revealing a potential role of 
inflammatory status in TB-DM patients(41). Furthermore, Leptin (a hormone related with 
appetite), which is usually higher in obese patients, inducing pro-inflammatory cytokines 
and Th1 response(40) is also altered in TB-DM patients, who were reported to have 
lower plasma levels of leptine compared TB non-DM patients, but both have a negative 
correlation between leptin levels and BMI(42).  However, not all this evidence is 
conclusive (leptin levels can be affected by multiple factors, such as diet)(43) and further 
research is required. 
 
A recent study in 3 provinces in Peru with the aim to evaluate modifiable risk factors for 
hypertension and DM, showed a pre-diabetes prevalence of 18%(7), lower than our 
study, leading us to hypothesize that TB participants potentially have a higher risk of 
developing DM in the following years.  However, the definition of pre-diabetes needs to 
be considered carefully, since infections can produce hyperglycemia in general(44, 45) 
and TB infections are also known to cause transient hyperglycemia (46-48).  The 
definition of pre-diabetes per se is under scrutiny because there is evidence showing that 
more than half of persons with pre-diabetes don’t develop diabetes after 10 years(49); 
thus, the use of the standard definition of pre-diabetes can lead to over-diagnosis and 
overmedication(50, 51), increasing potential unnecessary risks (stress, drugs adverse 
events) in a vulnerable population such as those with TB. A study in Tanzania showed 
that the glucose levels reduced after TB treatment finished(48), but also showed the 
association of hyperglycemia with bad TB treatment outcomes (death or treatment 
failure), so a suggestion based in this evidence should be a confirmatory glucose test after 
TB treatment finish for patients with hyperglycemia (pre-diabetes or newly DM 
diagnosed) to confirm as a case of DM or as a case of transient hyperglycemia. 
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This study, like any observational study, has limitations. First, not all eligible participants 
were possible to enroll in the study (77.8% among eligible were enrolled, described in 
Figure 1), while only 4 TB-DM were not enrolled. Possible reasons why these patients 
chose not to participate in our study are lack of time, fear of blood draw or receiving 
DOTS after clinic attention time.  This issue can make our DM prevalence result 
overestimated, however, the population who wasn’t enrolled are similar in age (mean age 
29.4 years; SD: 12.8) and gender (60%) distribution with the study participants, so we 
don’t expect a huge difference in the estimate. A second limitation is the small number of 
TB-DM individuals (n=44): some factors that we would expect to be associated with TB-
DM, such as smoking status(31, 52, 53), were not associated with TB-DM in our study 
population (none of our TB-DM participants has history of smoking). This unexpected 
result may be due to chance, with the small sample size leading to a lack of statistical 
power and also can be explained by the low prevalence of smoking among TB patients: a 
similar population in Lima (n=2131) reported around 97% of TB patient didn’t 
smoke(54).  
 
Nevertheless, our study has strengths:  all patients were screened for DM with HbA1c, a 
standardized and validated measure, so the risk of DM misclassification is lower in our 
study population. Secondly, while not necessarily representative of all individuals with 
TB in Peru, many areas in Lima (where the majority of TB patients live) are very similar 
in demographics and socio-economic characteristics as in our study sites, so we do not 
expect that our results would differ greatly in other parts of the city.  
 
WHO and the UNION (International Union Against Tuberculosis and Lung Diseases) 
recommend bi-directional screening for TB and DM in the last years (55, 56).  
Preliminary results in Peru in 600 DM patients screened for TB, showed that only one 
patient had active TB(57), however, when DM is screened among TB patients, our study 
showed a higher frequency of the comorbidity, specially in people over 35 years. The 
Peruvian National TB program uses Fasting Blood Glucose (FBG) for DM screening, 
but, a study in Peruvian population showed the use of HbA1c diagnosed more DM cases 
than FBG, specifically in low-income population (such as TB population)(15).  So, in the 
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Peruvian context, our recommendation based in these results and other local evidence is 
the implementation of HbA1c test for DM screening, specially for people over 35 years 
old and with BMI higher than 25kg/m2.  
 
In conclusion, TB-DM was associated with age and obesity, and more than 30% of the 
patients evaluated had hyperglycemia.  Further studies exploring the role of age, obesity 




Table 3.1:  Participant characteristics 
 
Characteristics Total (n=484) TB non-DM (n=440) TB-DM (n=44) P-value 
     
Median age (IQR) 31 (23-44) 28.5 (22-40) 51 (45-58.5) < 0.05 
Older 35 years old (%) 216 (44.6%) 177 (40.2%) 39 (88.6%) < 0.05 
     
Male (%) 279 (57.6%) 256 (58.2%) 23 (52.3%) 0.45 
     
Median BMI kg/m2 (IQR) 22.0 (19.9-24.4) 21.8 (19.8-24.0) 24.6 (21.7-27.5) < 0.05 
     
Median Waist-to-Hip Ratio 
(IQR) 0.88 (0.84-0.93) 0.88 (0.83-0.92) 0.96 (0.89-0.97) < 0.05 
     
Median HbA1c % (IQR) 5.5 (5.2-5.8) 5.4 (5.2-5.7) 10.3 (8-12.7) < 0.05 
     
Median Random Blood Glucose 
(IQR) mg/dl 97.2 (84.6-115.2) 95.4 (84.6-111.6) 196.2 (119.9-249.8) < 0.05 
     
Quintiles SES (%)*    0.14 
Q1: Poorest 135 (29.6%) 126 (30.4%) 9 (21.4%)  
Q2: Poor 97 (21.3%) 90 (21.7%) 7 (16.7%)  
Q3: Middle income 83 (18.2%) 70 (16.9%) 13 (31.0%)  
Q4: Upper middle income 76 (16.7%) 71 (17.2%) 5 (11.9%)  
Q5: Richest 65 (14.3%) 57 (13.8%) 8 (19.1%)  
     
Smear Result (%)    0.10 
Negative 168 (34.7%) 158 (35.9%) 10 (22.7%)  
Scanty 52 (10.7%) 49 (11.1%) 3 (6.8%)  
1+ 88 (18.2%) 76 (17.3%) 12 (27.3%)  
2+ 114 (23.6%) 99 (22.5%) 15 (34.1%)  
3+ 62 (12.8%) 58 (13.2%) 4 (9.1%)  
     
Previous TB Episode (%) 149 (30.8%) 139 (31.6%) 10 (22.7%) 0.22 
     
Coughing more 14 days (%) 413 (85.3%) 375 (85.2%) 38 (86.4%) 0.84 
     
Ever smoke (%) 45 (9.3%) 45 (9.3%) 0 (0%) 0.03 
     
Family history of DM (%) 76 (15.7%) 60 (13.6%) 16 (36.4%) <0.01 





Table 3.2:  Factors associated with DM among TB patients 
 
Factors Crude PR (95%CI) P-value Adjusted PR (95%CI) P-value 
     
Age      
18-35 years REF  REF  
35-45 years 3.4 (1.0-10.7) 0.04 3.5 (1.0-12.3) 0.05 
45-55 years 16.4 (6.3-42.3) <0.05 15.6 (5.2-47.1) <0.05 
55-65 years 17.3 (6.3-47.4) <0.05 14.4 (4.1-50.5) <0.05 
>65 years 8.9 (2.7-29.1) <0.05 7.9 (2.1-29.9) <0.05 
     
Male 0.8 (0.5-1.4) 0.5   
     
SES     
Q1 REF  REF  
Q2 1.1 (0.4-2,8) 0.87 0.8 (0.3-2.0) 0.60 
Q3 2.3 (1.0-5.3) 0.04 0.9 (0.4-2.1) 0.86 
Q4 0.9 (0.3-2.8) 0.98 0.5 (0.2-1.4) 0.16 
Q5 1.8 (0.7-4.6) 0.19 1.0 (0.4-2.5) 0.82 
     
Smear result Positive 1.8 (0.9-3.6) 0.09   
     
Previous TB Episode 0.7 (0.3-1.3) 0.2   
     
BMI     
Normal REF  REF  
Underweight 1.2 (0.4-3.4) 0.75 1.1 (0.4-3.4) 0.85 
Overweight 3.1 (1.7-5.9) <0.05 1.9 (1.0-3.7) 0.06 
Obese 6.9 (3.2-14.7) <0.05 2.7 (1.3-5.7) 0.01 
     
Family history of DM 3.1 (1.7-5.4) <0.05 1.6 (0.9-2.9) 0.13 
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Table 3.3:  Factors associated with pre-diabetes compared with non-DM TB patients 
 
Factors Crude PR (95%CI) P-value Adjusted PR (95%CI) P-value 
     
Age      
18-35 years REF  REF  
35-45 years 1.1 (0.8-1.7) 0.6 1.1 (0.7-1.6) 0.8 
45-55 years 1.3 (0.8-2.1) 0.3 1.3 (0.8-2.1) 0.4 
55-65 years 1.2 (0.6-2.3) 0.7 1.1 (0.6-2.2) 0.7 
>65 years 2.4 (1.7-3.6) <0.05 2.5 (1.7-3.6) <0.05 
     
Male 1.1 (0.8-1.4) 0.7   
     
SES     
Q1 REF    
Q2 1.1 (0.8-1.7) 0.5   
Q3 0.8 (0.5-1.4) 0.5   
Q4 0.8 (0.5-1.3) 0.3   
Q5 1.3 (0.9-2.0) 0.2   
     
Smear result positive 1.6 (1.1-2.3) <0.05 1.7 (1.2-2.3) 0.04 
     
Previous TB Episode 1.4 (1.0-1.8) 0.04 1.3 (0.9-1.8) 0.06 
     
BMI     
Normal REF    
Underweight 0.9 (0.5-1.4) 0.6   
Overweight 1.0 (0.7-1.5) 0.9   
Obese 1.6 (0.7-3.4) 0.2   
     
Family history of DM 1.0 (0.7-1.6) 0.9   
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Table 3.4:  Factors associated with DM among TB patients over 35 years’ old 
 
Factors Crude PR (95%CI) P-value Adjusted PR (95%CI) P-value 
     
Age      
35-45 years REF  REF  
45-55 years 4.8 (2.0-11.4) <0.05 4.5 (1.9-10.6) <0.05 
55-65 years 5.2 (2.0-13.1) <0.05 4.5 (1.7-11.9) <0.05 
>65 years 2.8 (0.9-8.4) 0.07 3.0 (1.0-9.0) 0.05 
     
Male 0.8 (0.5-1.4) 0.43   
     
SES     
Q1 REF    
Q2 0.7 (0.3-2.1) 0.60   
Q3 1.8 (0.8-4.1) 0.17   
Q4 0.6 (0.2-2.0) 0.45   
Q5 1.9 (0.8-4.7) 0.16   
     
Smear result Positive 1.5 (0.7-2.8) 0.3   
     
Previous TB Episode 0.6 (0.3-1.1) 0.09   
     
BMI     
Normal REF  REF  
Underweight 0.6 (0.1-2.4) 0.47 0.5 (0.1-2.2) 0.37 
Overweight 1.6 (0.8-3.1) 0.14 1.4 (0.8-2.6) 0.30 
Obese 3.7 (1.9-7.4) <0.05 2.6 (1.3-5.3) < 0.05 
     
Family history of DM 1.8 (1.0-3.3) 0.04 1.4 (0.8-2.5) 0.22 














 138 patients (60% Male, 
40% Female) 
 134 non TB-DM 
 4 TB-DM: 3 Male, 1 Female 
440 TB non-DM 44 TB-DM 
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To compare TB treatment outcomes among MDR-TB patients with and without DM. 
Design 
MDR-TB records from the operational patient’s database of Peru’s National TB Program 
were reviewed.  Adult patients who started MDR-TB treatment between 2010-2013 in 
Lima were included in the study. Cox regression was used to estimate crude and adjusted 
Hazard Ratios, evaluating factors associated with mortality. 
Results 
1999 adult MDR-TB patients started treatment between 2010-2013, 64.8% were male. 
The median age was 27 (IQR: 22-37) and 28.7% were over 35 years old. Median BMI 
was 21.8kg/m2 (IQR: 19.5-24.0), 19.3% had a BMI>25kg/m2, median blood glucose level 
85.8mg/dl (IQR: 77-96) and HIV prevalence was 3.4%. The overall prevalence of DM 
among MDR-TB was 6.4% (95%CI: 5.4%-7.6%). Being older than 35 years old, 
BMI>25kg/m2 and glucose200mg/dl were all associated with DM among MDR-TB 
patients (p-value<0.05). Mortality was higher among MDR-TB patients with DM 
(19.5%) compared to patients without DM (7.1%) and after adjustment for several 
confounding factors, MDR-TB patients with DM were three times as likely to die 
(aHR=2.9 95%CI:1.4-5.9; p-value< 0.05). 
Conclusions 
MDR-TB patients with DM have greater mortality than those without DM, and are 
generally older, more overweight/obese and tend to have higher mortality risk compared 
with MDR-TB patients without DM.  
 





Multidrug Resistant Tuberculosis (MDR-TB) is a big threat for TB control, especially in 
low-and-middle income countries (LMICs).  Almost half millions of TB patients had 
MDR-TB worldwide and almost 10% of them had XDR-TB (Extensively drug-resistant 
TB) in 2015(1). Peru is one of the Latin America countries with the highest burden of 
MDR-TB, with almost 30% of estimated MDR-TB cases in the Americas in 2015(1) and 
the prevalence of MDR-TB among new and previously TB cases with 5.3% and 20% 
respectively. Diabetes (DM) prevalence is increasing worldwide in recent years (9.1% in 
2015), but specifically in low-and-middle income countries (LMICs)(2), and the national 
prevalence in Peru is around 7%(3). There is an increasing risk of infections (such as TB)  
if DM patients lack adequate glucose control (4), and in settings such as Peru there is a 
lack of good glucose control(5). The risk of not reducing the rise of DM prevalence could 
be to not reach TB control goals by 2035 as is showed by a mathematical model, delaying 
TB control goals (6).  The association between TB-DM showed a higher risk for bad TB 
treatment outcomes(7). Furthermore, people living with HIV have higher risk for TB, 
however the population at risk is higher among DM, with Population attributable fraction 
(PAF) between 15-25, compared with HIV (PAF=12)(8).   
 
Among the multiple risk factors associated with MDR-TB, one important risk factor is 
DM(9-11).  The DM prevalence among MDR-TB patients is ranges from 10%-60%(9, 
10) and the odds of having MDR-TB among DM patients is almost 2 times compared 
with non-DM patients(12, 13). The clinical presentation of MDR-TB among patients with 
DM were reported as more severe: there is evidence of the association of primary MDR-
TB and DM, increasing the time for sputum culture conversions(14, 15), and also the 
extension of lung damage seems to be bigger than sensitive TB(16).  Studies reported that 
MDR-TB patients with DM are usually older (over 35 years old) and have a higher Body 
Mass Index (BMI) compared with non-DM patients (16, 17).  
 
Due the lack of evidence of treatment outcomes among MDR-TB Peruvian patients and 
its association with DM, we analyzed a cohort of MDR-TB patients in Lima-Peru 
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between 2010-2013, to determine the DM prevalence and factors associated with MDR-




Setting and Study Design 
We performed a retrospective cohort study using the operational MDR-TB database from 
the Peruvian National TB Program. This database registers all Peruvian MDR-TB cases 
and links with electronic clinical TB records, which includes demographic information, 
anthropometric measures, TB information (bacteriological and drug sensitivity results), 
comorbidities (HIV and DM) and TB treatment outcomes.   
 
Population 
Adult patients (older than 18 years old) who started MDR-TB treatment between January 
2010 and December 2013 in Lima were included in the study. We consider only the first 
episode of MDR-TB registered during the study period and its treatment outcome.  
 
Study definitions 
All participants were defined as a MDR-TB case. MDR-TB diagnosis (based in DST of 
isoniazid and rifampicin) was the same for all patients and used DST techniques. 
Diabetes was routinely requested for screening to all MDR-TB patients as a part of 
baseline laboratory test (fasting blood glucose), and DM diagnoses were abstracted from 
the patients’ medical records. TB treatment outcomes were categorized according to 
WHO guidelines: cure, treatment completed, default, death and treatment failure.(18). 
Our primary outcomes were 1) death and 2) a composite bad treatment outcome (BTO) 
consisting of death, default or treatment failure. 
 
Statistical Analyses 
We used STATA 13.0 (StataCorp, Texas, USA) for all analyses. Continuous variables 
were summarized using median and interquartile ranges (IQR), and categorical variables 
were summarized using frequencies. Analyses between groups were done using the 
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Mann-Whitney U test for non-parametric data, and using Chi-squared test for categorical 
variables. The log-rank test was used to compare Kaplan-Meier survival curves. Cox 
regression model was used to estimate crude and adjusted Hazard Ratios, evaluating 
factors associated with mortality among MDR-TB patients. The proportional hazard 
assumptions were checked using Schoenfeld residuals.  
 
Because this dataset is an operational National TB program database, there are missing 
values of some variables.  The frequency of missing values was higher than 10% but 
under 20% for BMI25kg/m2 (17.5%) and DST result for pyrazinamide and ethambutol 
resistance (19.3%), we did multiple imputation of missing variables using regression 
models with a multivariate normal distribution (MVN) imputation procedure, under the 
assumption that these variables were missing at random (MAR)(19).  
 
Institutional Review Board Approval 
The dataset was de-identified before analysis to protect the confidentiality of the patients. 






1999 MDR-TB adult patients were started treatment during the study period and were 
included in this analysis. The median age of these patients was 27 years (IQR: 22-37) and 
1296 (64.8%) were male. DM prevalence was 6.4% (95%CI 5.4%-7.6%). MDR-TB 
patients with DM were older (median 52 years vs 26 years) and had higher BMI (median 
23.0kg/m2 vs 21.6 kg/m2) compared with MDR-TB patients without DM (Table 4.1).  
Frequency of having a prior episode of TB was similar between groups (6.1% vs 6.3%), 
and the median number of previous TB treatments was 1 for both groups (Table 4.1). 
Patients with DM (1.6%) had lower HIV prevalence compared to those without DM 
(3.5%).  
 
MDR-TB treatment outcomes and mortality 
During MDR-TB treatment, 158 (7.9%) deaths occurred, 25 (19.5%) among patients with 
diabetes compared to 133 (7.1%) among patients without DM (p=0.05) (Figure 4.1). 
Regarding BTO, there was not difference between patients with and without DM (36.0% 
vs. 40.6%; p-value: 0.3) (Table 4.2). After adjustment for age, sex, BMI, inmate status, 
HIV, previous TB treatment, positive AFB smear at beginning of treatment, RBG over 
200mg/dl and full resistance to 1st line of TB drugs (isoniazid, rifampicin, ethambutol and 
pyrazinamide), patients with DM had 2.9 times the hazard for death compared with 
patients without DM (adjusted Hazard Ratio aHR: 2.9; 95%CI 1.4-5.9) (Table 4.3).  
 
Because BMI and DST result for ethambutol and pyrazinamide had missing data, we did 
a MVN imputation procedure (Appendix Table 4.1 and Appendix Table 4.2). Almost all 
of the associations remained similar, with the exception of full resistant for 1st line of TB 






Mortality was higher among MDR-TB patients with DM compared with non-DM 
patients (19.5% vs 7.9%).  MDR-TB patients with DM were older and had a higher 
median BMI compared with MDR-TB without DM in our study population.  Our findings 
show that bad treatment outcomes frequency was similar among DM and non-DM 
patients.  Also, we found that DM prevalence among MDR-TB patients over 35 years old 
was higher than the DM prevalence reported in the general adult Peruvian population 
(19.9% vs 7.0%)(3), showing DM as a more common comorbidity than HIV in this 
population.  These findings provide evidence of the urgent necessity to implement a 
comprehensive approach for MDR-TB and DM management, considering the increasing 
prevalence of DM in LMICs settings including Peru and the increased risk of mortality in 
these patients. 
 
An increased risk for negative TB treatment outcomes has been reported in patients with 
TB-DM in several studies(20-23).  A meta-analysis showed a Risk Ratio (RR) of 1.7 
(95% CI:1.4-2.1) for bad treatment outcomes and 1.9 (95% CI:1.5-2.4) for death among 
TB-DM patients compared with TB without DM (7). Also, compared patients with drug-
susceptible TB, MDR-TB patients have been reported to have higher mortality risk and 
this mortality was associated with DM, HIV, lower education and number of previous TB 
episodes(24).   
 
Our findings are similar to results presented by other studies on MDR-TB and TB in 
different settings.  One study in Korea(21) found similar characteristics (older age and 
higher BMI) and higher risk of death among MDR-TB patients with DM; however, they 
found higher risk for treatment failure, which we did not find.  One explanation can be 
the difference in treatment successful rate:  in our cohort was 63.7% overall, higher 
compared with Korea (45.3%).)  Studies in Egypt and China reported DM as a risk factor 




The role of glucose in MDR-TB and TB in general is not well understood. People with 
poor glucose control have a higher risk of developing active TB (27) and a higher risk for 
poor treatment outcomes(28, 29). DM patients had an impaired immune system (innate 
and adaptive immunity)(30, 31), affecting host’s response against M. tuberculosis, with a 
lower interaction between monocytes and M. tuberculosis in TB-DM patients with poor 
glucose control(32).  Similar results were found in other infections, where glucose control 
plays an important role in infection control among DM patients(4). Severe TB also 
appears to be more common among DM patients with uncontrolled glucose (HbA1c7%) 
compared with DM patients with good glucose control (HbA1c<7%), presenting more 
lung cavities and longer time for culture conversion(33) and poor treatment response(34).  
Unfortunately, our database didn’t have a complete record of chest X-ray (only 58.5% of 
the patients had x-ray data), showing that there was not difference between patients with 
DM compared with patients without DM. Also, time to culture conversion was not 
routinely recorded, and HbA1c testing was not routine in this population. This inadequate 
glucose monitoring unfortunately is very common among DM patients in Peru, mainly 
because the inability of Peruvian health system to provide adequate glucose monitoring 
and DM care for DM patients)(35, 36). 
 
Hyperglycemia is common in several infections(37). Regarding TB, a study in Tanzania 
evaluated hyperglycemia at TB diagnosis and the glucose level at the beginning and end 
of TB treatment comparing with non-TB controls and found in many cases 
hyperglycemia was transient, disappearing after TB treatment ends, however, 
hyperglycemia was associated with poor TB treatment outcomes(38). To reduce the 
potential DM misclassification, a confirmatory DM test should be done after the 
completion of MDR-TB treatment. 
 
TB treatment is also affected by DM:  there are changes in pharmacokinetics (specifically 
in rifampicin) among TB with DM patients compared with TB without DM patients, with 
a lower Area-under-curve (AUC) between 0-6 hours(39).  We did not find 
pharmacokinetics studies evaluating 2nd line drugs for MDR-TB patients, however 
studies on DM and other infectious diseases showed a difference in antibiotic absorption, 
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associated with impaired renal function(40).  Renal function in DM patients is affected by 
glucose control and high BMI, affecting one 2nd line drug type (for example 
aminoglycosides), this is why it is necessary to adjust the doses of this drug among DM 
patients(40, 41). 
 
This study has limitations.  The database is from the operational MDR-TB national 
database, thus has a high risk of information bias. Many key variables were complete 
(DM status, treatment outcome, age, gender), but others have missing data (HIV, BMI, 
chest X-rays, DST results). Nevertheless, after handling missing data with multiple 
imputation, we observed very similar measures of association, suggesting a similar 
strength and direction of the association. Other unmeasured confounders known to be 
associated with TB outcomes, such as HbA1c (due its higher cost and low availability at 
health centers in Lima), renal function tests (creatinine), smoking status, alcohol 
consumption and DM comorbidities, were not routinely recorded in this cohort, however 
many of these confounders are now registered in the National TB Register, and can be 
used to improve clinical management and support.  
 
Our study also has several strengths. First, we were able to evaluate all the population 
with MDR-TB diagnosis in Lima during the study period, reducing the risk of selection 
bias; also; additionally, treatment outcomes were recorded for all study patients, making 
our results a good approximation of the reality of MDR-TB in Lima during the study 
period. DM status was routinely tested as a part of baseline laboratory tests (fasting 
glucose) for all MDR-TB patients and was abstracted from clinical records for this study, 
so this reduce the risk of underestimation of DM prevalence.  
 
Testing for DM and recording DM status for TB patients should be universal for this 
population: Our results in addition with other evidence (42) show the necessity of a 
comprehensive approach for DM diagnosis and management for TB and MDR-TB 
patients, including the implementation of HbA1c test at TB clinics, with the aim to 
improve glucose monitoring and DM diagnosis and control.   
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In conclusion, our study showed a higher prevalence of DM among MDR-TB patients 
over 35 years old and the association of DM status with higher risk of mortality among 
MDR-TB. Further studies are necessary to evaluate the role of glucose control among 
MDR-TB patients with DM in addition with research in the interaction between MDR-
TB treatment and DM management and therapy with the aim to improve MDR-TB 
treatment outcomes. Universalization of glucose tests (including HbA1c) and the 
implementation of a comprehensive TB-DM care program should be addressed to reach a 
better management of MDR-TB patients with DM.  
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Tables 
Table 4.1.- Clinical characteristics of MDR-TB patients with and without DM 
(n=1999) 
 





     
Media Age (IQR) 27 (22-37) 26 (22-34) 52 (44-59) < 0.05 
Age over 35 (%) 574 (28.7%) 460 (24.6%) 114 (89.1%) <0.05 
Male (%) 1296 (64.8%) 1218 (65.1%) 78 (60.9%) 0.3 
Median BMI (IQR) (n=1652) 21.8 (19.5-24.0) 21.6 (19.5-23.9) 23.0 (10.7-27.1) <0.05 
BMI  25kg/m2 (%) (n=1652) 318 (19.3%) 283 (18.3%) 35 (34.7%) <0.05 
Inmate (%) 141 (7.1%) 130 (7.0%) 11 (8.6%) 0.5 
HIV positive (n=1930) 65 (3.4%) 63 (3.5%) 2 (1.6%) 0.3 
Cavitary disease (%) (n=1169) 461 (39.4%) 432 (39.4%) 29 (40.3%) 0.9 
Median number of previous TB 
treatments 1 (1-2) 1(1-2) 1(1-2) 0.8 
 2 previous TB treatments 917 (45.9%) 858 (45.9%) 59 (46.1%) 0.9 
Median months on treatment 19 (14-22) 19 (14-22) 20 (14-24.5) 0.08 
Positive AFB smear at treatment 
start 1546 (77.3%) 1440 (77.0%) 106 (82.8%) 0.1 
Resistant to Ethambutol and 
Pirazinamide (n=1614) 459 (28.4%) 429 (28.4%) 30 (29.7%) 0.8 
Median glucose mg/dl (IQR) 
(n=1934) 85.8 (77-96) 85 (76-94) 155.9 (115.4-236) <0.05 
Glucose  200 mg/dl (%) 
(n=1934) 54 (2.8%) 13 (0.7%) 41 (33.1%) <0.05 
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Table 4.2.- Initial treatment outcomes among MDR-TB patients with and without 
DM (n=1999) 
 





     
Cured (%) 880 (44.0%) 830 (44.4%) 50 (39.1%) 0.5 
Treatment completed (%) 393 (19.7%) 367 (19.6%) 26 (20.3%) 0.9 
Default (%) 514 (25.7%) 493 (26.4%) 21 (16.4%) 0.3 
Death (%) 158 (7.9%) 133 (7.1%) 25 (19.5%) 0.05 
Treatment failure (%) 54 (2.7%) 48 (2.6%) 6 (4.7%) 0.8 
Bad treatment outcome* (%) 726 (36.3%) 674 (36.0%) 52 (40.6%) 0.3 




Table 4.3.- Associate factors with mortality among MDR-TB patients (n=1564) 
 
Factors Crude HR (95% CI) p-value Adjusted HR (95%CI) p-value 
     
DM  2.6 (1.7-4.0) <0.05 2.9 (1.4-5.9) <0.05 
Age over 35 (%) 2.3 (1.7-3.1) <0.05 2.1 (1.3-3.3) <0.05 
Male (%) 0.9 (0.7-1.3) 0.6 1.1 (0.7-1.8) 0.6 
BMI  25kg/m2 (%)  0.2 (0.1-0.5) <0.05 0.2 (0.1-0.5) <0.05 
Inmate (%) 0.9 (0.5-1.7) 0.8 0.7 (0.3-1.5) 0.3 
HIV positive 4.4 (2.7-7.2) <0.05 4.3 (2.3-8.0) <0.05 
 2 previous TB treatments 1.2 (0.8-1.6) 0.4 1.1 (0.7-1.7) 0.6 
Positive AFB smear at 
treatment start 0.8 (0.6-1.2) 0.3 0.7 (0.5-1.1) 0.1 
Glucose  200 mg/dl (%) 2.0 (1.0-4.0) 0.06 0.6 (0.2-1.7) 0.3 
Resistant to Ethambutol and 
Pyrazinamide 1.8 (1.3-2.6) <0.05 2.0 (1.3-3.0) <0.05 





Figure 4.1.- Kaplan-Meier survival analysis for mortality at 36th months of 










Appendix Table 4.1.-  Full data and Multiple Imputation data 
 
Factors Full data  Coefficient (SE) p-value 
Multiple Imputation  
Coefficient (SE) p-value 
     
DM  1.1 (0.4) <0.05 0.8 (0.3) <0.05 
Age over 35 (%) 0.7 (0.2) <0.05 0.7 (0.2) <0.05 
Male (%) 0.1 (0.2) 0.6 -0.1 (0.2) 0.6 
BMI  25kg/m2 (%)  -1.5 (0.4) <0.05 -1.2 (0.3) <0.05 
Inmate (%) -0.4 (0.4) 0.3 -0.3 (0.3) 0.4 
HIV positive 1.5 (0.3) <0.05 1.3 (0.3) <0.05 
 2 previous TB treatments 0.1 (0.2) 0.6 0.1 (0.2) 0.5 
Positive AFB smear at 
treatment start -0.3 (0.2) 0.2 -0.2 (0.2) 0.2 
Glucose  200 mg/dl (%) -0.6 (0.6) 0.2 -0.2 (0.4) 0.7 
Resistant to Ethambutol and 
Pyrazinamide 0.7 (0.2) <0.05 0.4 (0.2) 0.02 
     
 
SE: Standard Error 
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Appendix Table 4.2.- Associate factors with mortality among MDR-TB patients 
using Multiple Imputation dataset 
 
Factors Adjusted HR (95%CI) p-value 
   
DM  1.5 (1.3-1.8) <0.05 
Age over 35 (%) 2.2 (2.0-2.4) <0.05 
Male (%) 1.0 (0.9-1.0) 0.3 
BMI  25kg/m2 (%)  0.4 (0.4-0.5) <0.05 
Inmate (%) 0.8 (0.7-1.0) 0.3 
HIV positive 3.0 (2.5-3.5) <0.05 
 2 previous TB treatments 1.0 (0.9-1.1) 0.8 
Positive AFB smear at 
treatment start 0.9 (0.8-1.0) 0.2 
Glucose  200 mg/dl (%) 1.1 (0.8-1.3) 0.6 
Resistant to Ethambutol and 
Pirazinamide 1.1 (1.0-1.2) 0.2 
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5. Chapter Five: Conclusions and Recommendations 
 
5.1 Summary of Major Findings 
The results discussed in this dissertation highlight the rising importance of DM in TB 
control, especially in LMICs countries like Peru, where TB control, although started to 
have a slowly decrease in TB prevalence(1), can be affected by the increasing DM 
prevalence(2).  Despite the evidence of the DM effect in TB clinical presentation, and its 
association with poor TB treatment outcomes was reported several years ago(3-7), there 
are still questions to solve and gaps in the evidence to fill.   
 
In Peru, as one of the countries with high burden of TB in Latin America and with the 
higher number of cases of MDR-TB in the region(1), comorbidities such as DM can put 
in risk any potential strategy to control. The lack of a strong health system, which affect 
not only TB program, but also DM programs, make complex the approach for a 
comprehensive management of TB-DM comorbidity. Most of the results presented here, 
even though are based in Peruvian population, provide a good approach of DM situation 
in a LMIC, providing evidence that can help (and in some cases extrapolate) in other 
settings similar as Peru. 
 
These results in first place, despite the increasing number of publication on TB-DM in 
the last years, the methodological quality of these studies are no totally adequate and can 
prone to biased results.  Secondly, describe a clear figure of high DM prevalence among 
TB patients over 35 years old with higher levels of HbA1c (a proxy of poor DM care and 
glucose management). Third, this dissertation showed DM is a more frequent 
comorbidity for TB patients than HIV. Fourthly, and last, mortality in MDR-TB patients 
with DM is frequent and should be observed in detail in this population, with the aim to 
reduce it. 
 
5.1.1. Paper I  
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Paper 1 showed, after a very wide and comprehensive search (with more than 16000 hits 
to screen from 4 references databases and more than 300 papers reviewed in full) and the 
meta-analysis of 11 papers, in countries with double burden of TB & DM, TB-DM 
patients had higher risk for death compared with TB non-DM patients (2.5 times higher), 
and when poor TB treatment outcome is evaluated, the risk is 2.6 times higher among 
TB-DM patients compare with TB non-DM patients.  These results confirm previous 
systematic review(8), which was done mainly with primary studies from high-income 
countries.  Furthermore, the measure of association is stronger in our review compared 
with the previous one(8), suggesting a stronger association in settings with several 
problems regarding TB & DM and dealing with structural problems in their health 
systems. 
 
A sensitivity analysis was done only in studies with prospective glucose test to confirm 
DM status, reducing the risk of DM misclassification, and the results remained similar 
(pRR for Death was 2.5 and the pRR for poor TB treatment outcome was 2.5), 
confirming our previous results.  Regarding limitations, there is low risk for publication 
bias based on the funnel plot, however this study has limitations on the poor quality of 
the studies and inadequate analysis (due the lack of confounding control)(9). 
 
5.1.2. Paper II 
 
Our results showed a DM prevalence among TB patients of 9.1%, but this prevalence 
doubles (18.1%) in patients older than 35 years of age.  Compared with studies in general 
population in Peru(10, 11), our results showed a higher prevalence of DM among TB 
patients.  Compared with HIV, DM seems to be a more frequent comorbidity among TB 
patients (9.1% vs 1.9%). 
 
These results are consistent with the evidence that we found in the literature: TB-DM 
patients have as common associate factors older age, higher BMI and higher HbA1c.  In 
our case, the median BMI was almost 25kg/m2 and the median HIbA1c was 10.3%, 
reflecting a population with overweight (in a population such as TB patient who are 
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usually underweight) and with higher levels of glucose (reflecting a chronic poor glucose 
control).   
 
Another interesting finding is the important percentage (around 26%) of TB patients with 
high levels of glucose (defined as pre-diabetes: HbA1c values between 5.7%-6.4%).  This 
levels of glucose can be explained by the frequent hyperglycemic status occurred in 
infection, and specifically in TB patients, who apparently have transient hyperglycemia, 
with lower glucose levels at the end of TB treatment.  However, a study in Tanzania 
showed an association between these high levels of glucose with poor TB treatment 
outcome(12), reason why our results, showing a high frequency of hyperglycemic TB 
patients,  should alert to the TB care team to observe closely these patients with the aim 
to reduce the risk of poor TB treatment outcomes.  
 
5.1.3. Paper III 
 
MDR-TB (one of the biggest threats for TB control in Peru) and its association with DM 
was discussed in Paper 3.  This study, with a cohort of almost 2000 patients, including all 
MDR-TB patients in Lima between 2010 to 2013, had the aim to evaluate TB treatment 
outcomes.  The findings showed similar epidemiological patterns observed in Paper 2: 
MDR-TB patients with DM were older and heavier (almost 35% of MDR-TB patients 
with DM were overweight or obese) compared with MDR-TB patients without DM.  The 
prevalence of DM among this population was almost 7%, however, when the prevalence 
of DM is restricted for MDR-TB patients over 35 years old, almost 20% of them had 
DM.  
 
Regardless our results didn’t find a difference in poor TB treatment outcomes among 
MDR-TB patients with DM and MDR-TB patients without DM, the frequency of 
mortality among MDR-TB patients with DM was much higher compared with MDR-TB 
patients without DM (19.5% vs 7.9%). Also, DM prevalence among MDR-TB patients 
was higher than HIV prevalence (3.4%), making DM a more frequent comorbidity among 
MDR-TB patients with a higher risk for death (aHR=2.9). Despite the logical limitations 
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that usually appear in studies as the one conducted (using an operational dataset), since 
the study include all the population available, is a very good description of the DM 
situation among this MDR-TB population, and alert to the TB health workers to pay 
attention in MDR-TB patients with DM, because they high higher risk to death. 
 
5.2. Study Limitations 
 
In Paper 1, main limitations are referred to the methodological quality among primary 
studies.  The majority of them was not designed to evaluate the association TB-DM 
and/or used operational data from national TB programs.  Also, DM status was not 
always defined with a prospective glucose test, leading to potential misclassification of 
DM status.  Other methodological limitations were the lack of adjusting for confounding 
in most papers that were reviewed, and the population characteristics was mainly based in 
TB usual reported characteristics (age, gender, smear results) but not in DM factors 
(glucose level, BMI, waist circumference, lipids levels, blood pressure), so there is a high 
risk of unknown confounders not considered in primary study results.  Finally, some 
studies had missing data, and was not addressed in the primary studies, increasing the risk 
of bias.  However, the results keep the same direction than the previous review, with the 
advantage that this is focused in countries which struggle with weak health systems and 
with different epidemiology for TB and DM. 
 
Our results in Paper 2 came from a prospective cohort, which took longer time that we 
expect and planned at the beginning, and the main reason for this delay was the lower 
prevalence of DM that was expected.  We started with 3 clinics, and after one year when 
recruitment was slow (specially in TB-DM participants) we decide to include one more 
clinic, to speed up the recruitment. Regardless the TB-DM prevalence was lower than we 
expect, and lower than in the other TANDEM sites, the prevalence of 9.1% was higher 
than the prevalence found in general population in Peru(11).  Another issue we faced 
during the recruitment were strikes from health workers at the primary care clinics where 
we recruit (one of the strikes takes more than 4 months).  Our good relationship with the 
health workers permit us to enroll patients during these months, but because during the 
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strike doctors didn’t attend all the patients who visit the TB clinic for diagnosis and 
treatment, our recruitment was slower during these months.   
 
Although the use of the National TB program MDR-TB dataset for Paper 3 was a rich 
source of information, as any operational dataset, had some limitations:   missing data 
(identified as missing at random) was frequent in a key variable (BMI), chest X-Ray 
results and (in much lower frequency) HIV status.  Also, DM status information was 
recorded as a binary variable, and more info (date of diagnosis, comorbidities, DM 
complications, HbA1c) were not available, reason why was not possible to have a better 
characterization of this population.  Nevertheless, this study was done in close 
collaboration with the Peruvian National TB program, providing access to clinical 
records in the cases who had missing data, reducing the amount of final missing data and 
provide an almost 2000 MDR-TB patients cohort.  Further analysis with the new cohort 
of patients are planned with the National TB program, with the lessons learned in this 
study to catch as much information as possible. 
 
5.3. Recommendations for future research  
Our results provide more evidence for a better understanding of TB-DM in Peru and in 
similar settings; however, there are still many questions to solve to address this problem. 
Future research should cover the following areas: 
 
 Epidemiological studies:  Although there are some studies exploring TB-DM in 
Peru before our work (13-16), there is still a lack of epidemiological information 
for a better understanding of TB-DM problem in a Peruvian context, in part by the 
lack of primary designed TB-DM studies (all TB-DM previous studies in Peru 
before our work are a secondary analysis and/or based on clinical records, which 
is prone for bias and confounding), but also because DM epidemiological 
information is still not complete: just only in recent years started to appear better-
designed studies in DM and other NCDs in Peru(17-21) for a better 
comprehension of DM situation in Peru. Nowadays there is a great opportunity to 
fill these information gaps because the Peruvian TB program has, since 2015, a 
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new electronic database (SIGTB)(22) to register all clinic and demographic 
information among all TB patients in Peru, making SIGTB a great and helpful 
tool to fill gaps on the TB-DM epidemiological background knowledge in Peru.  
This electronic database is linked with a unique identifier for TB patients, so in 
next years will be possible to evaluate the risk of relapse and the epidemiological 
pattern in Peruvian TB-DM population (such as M. tuberculosis resistant pattern 
in this population for example).  Also, considering TB-DM population is older 
compared with general TB population, epidemiological characteristics and risk 
factors for TB should be evaluated in people over 35 years old to identify 
potential risk factors, with the aim to implement prevention activities tailored to 
this population.  The evidence that could arise from these studies will help to 
bring more information with higher quality about TB-DM in LMICs, because still 
many of the studies on TB-DM were made in high income countries, with 
different level of health systems and with a lower TB prevalence, thus making it a 
completely different scenario for TB-DM compared with LMICs’ settings.  
 
 Operational research: Many problems around TB-DM (and in TB in general) are 
based in the complexity and needs of health systems at LMICs like Peru.  We just 
started in mid-2016 a study in collaboration with the Peruvian TB Program to 
identify the gaps and barriers in health system that affect TB-DM patients.  This 
study’s (“cascade of care of TB-DM”) approach was used before in HIV(23-26) 
and there are examples in DM(27, 28) and TB(29) too.  We realized during the 
prospective study (Paper 2), the many weaknesses in the Peruvian health system 
to provide basic support in DM management and care, despite it is fully covered 
(diagnosis, treatment and medical care for free for TB patients) by the National 
Insurance Program (called Seguro Integral de Salud – SIS in spanish)(30).  One of 
the most frequent barriers that we identify in the interaction with the participants 
in the prospective study was the lack of endocrinologist or a DM trained health 
worker at the primary health care, making very difficult the DM care for TB 
population, because, under Peruvian DM guidelines, any patient with DM who is 
diagnosed with TB should be evaluated and clinical managed by an 
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endocrinologist.  Another important barrier we identify was the lack of tests for 
DM (fasting glucose and HbA1c):  HbA1c is still very difficult to access in the 
biggest national hospitals in the country, since there is a shortage of reagents. We 
expect that the lessons learned as a result of this operational research would help 
with better evidence for TB-DM care in settings similar to Peru, where TB 
prevalence is still high and DM prevalence is increasing. 
 
 Better reporting and data quality: The big problem that arises in our systematic 
review (and in the previous one, published in 2011(8)) was the low 
methodological quality of TB-DM research, leading us to deal with several issues 
on bias and unmeasured confounders (and in some cases, with the role of chance, 
because the studies were underpowered).  Despite the evidence of the association 
between TB-DM with poor TB treatment outcomes is relatively strong, due to the 
complexity of DM clinical presentation, future studies should consider not only 
the classic confounders used in TB research (age, gender, socio-economic status, 
BMI, level of education) but also confounders such as HbA1c (or other glucose 
tests as fasting blood glucose or OTTG), time with DM diagnosis, DM 
comorbidities, blood pressure, lipids levels and DM treatment to characterize 
better this population and with the aim to reduce the role of confounding when the 
association between DM and TB treatment outcomes is evaluated. Unfortunately, 
this is very common in TB research(31), because many studies uses operational 
data from TB national programs (as in our Paper 3), observing problems such as 
missing data, representativeness and lack of important confounders for example.   
 
5.4 Policy Implications  
 
Our results highlight the strong association between two important diseases (TB and DM) 
in Peru, and, despite the limitations in these studies, this dissertation’s results have policy 
implications for the control of TB-DM in an urban area in Peru (and potentially can be 
extrapolate to similar settings).   An effective control among TB-DM would reduce the 
impact of DM in TB patients in Peru, a setting with several issues threatening TB control, 
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like a high prevalence of drug resistance (with the higher number of MDR-TB in the 
Americas)(1) and a scenario with a projected increasing of DM prevalence in the next 10 
years(32).  Our findings in our systematic review (Paper 1) supports previous evidence 
regarding the special attention that should be focused in TB treatment outcomes among 
TB-DM patients, which seems to have a stronger association with poor TB treatment 
outcomes in countries with high burden for both diseases.  In Peru, there are several 
issues regarding adherence and treatment intermittency (factors directly associated with 
treatment outcomes), which, unfortunately was not possible to address in the systematic 
review (due the lack of reporting of these factors by primary studies), but should be 
observed in detail during treatment monitoring of TB-DM patients, based on the evidence 
of higher risk for poor TB treatment outcomes.   
 
Our results in Paper 2 showed the high prevalence of DM among TB patients over 35 and 
with a BMI> 25 kg/m2, showed the urgent necessity to tailored the TB program 
(including DOT) for this population, with implementation of DM nutrition counselling 
and universal glucose testing (HbA1c if there are resources available, if is not at least 
with 2 times fasting blood glucose) among this population. Right now, the glucose testing 
at TB diagnosis is around 60% in Peruvian TB patients and is done using fasting blood 
glucose (Personal communication: Peruvian National TB program), leaving almost 40% 
of TB patients in Peru without known their DM status.  The lack of glucose test is mainly 
explained on the logistic capacity of the primary care center, where very often there is a 
lack of reagents.  Also, during our prospectively work on Paper 2, we observed through 
our interaction and interviews with the participants and TB health workers, the urgent 
need to stablish a good channel for interaction between TB program and DM programs, 
because in settings like Peru, where NCDs control programs usually are neglected, the 
interaction for referral between services is very complicated, but should be addressed(33-
36).  Previous experiences in TB-HIV program integration maybe can provide some 
evidence and hints to how integrate TB and DM programs(37, 38).  
 
In our Paper 3, we explore the role of DM among MDR-TB population in Lima, showing 
an increased risk for death among this population.  Our findings demonstrate the 
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necessity among these patients to have a close glucose monitoring and DM care, 
including further evaluation on DM complications to reduce the risk of death.  Although 
the mortality described in our Paper 3 didn’t stablish if the cause of death was TB or not, 
evidence showed DM mortality in settings like Peru is caused by many reasons such as 
stroke, renal failure and infections(2), and these patients should be evaluated also in their 
blood pressure, renal function and lipids levels, with a comprehensive DM and 
cardiovascular evaluation to reduce mortality risk.  Age should be considering also an 
important factor for MDR-TB patients with DM: our findings showed an older population 
compared with MDR-TB without DM, and tailored TB programs (as is suggested above) 
should be done for this population.  
 
Finally, an important policy implication as a result of our findings is the higher frequency 
of comorbidity TB-DM than TB-HIV in these populations: in Paper 2 TB-DM was 9.1% 
and in TB-HIV was 1.9%; in Paper 3 HIV in MDR-TB population is around 4%, 
however DM prevalence (as we stated in the limitations in Paper 3, can be this prevalence 
underestimated) is higher (6.4% in whole study population, with almost 20% DM 
prevalence among patients over 35 years old). As we noted above, TB-DM program 
integration (observing previous experiences in TB-HIV services) should be addressed to 
achieve an adequate control of TB-DM problem. 
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